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Abstract
Each year, thousands of people die from heart disease and related illnesses due to
the lack of available donor organs. Left ventricular assist devices (LVADs) aim to
mitigate that occurrence, serving as a bridge-to-surgery option. While short term
survival rates of LVAD patients near that of orthotopic surgery they are not viable
long term options due to varied reasons. This work examines one cause, outlet graft
thrombosis, and develops an algorithm for increasingly robust classification of device
condition as it pertains to thrombosis or more generally occlusion. In order to do
so an in vitro heart simulator is developed so that varying degrees of signal nonstationarity can be simulated and tested over a wide range of physiological blood
pressure and heart rate conditions. Using a seeded-fault methodology, acoustics are
acquired at the LVAD outlet graft location and subsequent spectral images of the
sounds are developed. Statistical parameters from the images are used as features for
classification using a support vector machine (SVM) which yields promising results.
Given a comprehensive training space classification can be performed to fair accuracies
(roughly 80%) using only the spectral image parameters. However, when the training
space is limited augmenting the image features with patient state parameters elicits
more robust identification. The algorithm developed in this work offers non-invasive
diagnostic potential for LVAD conditions otherwise requiring invasive means.
Thesis Supervisor: Dr. Jason Kolodziej
Title: Associate Professor
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Chapter 1
Introduction
Left ventricular assist devices (LVADs) are commonly used as a bridge to surgery
treatment option for patients with advanced heart conditions. This is mainly due to
the large disparity between transplant candidates and compatible/available donors.
In the United States, roughly 15% of eligible candidates receive a donor heart [18]. In
less developed countries there is a much more significant gap, nearing an estimated
transplant rate of less than 1% of possible cardiac transplants met [18]. When first
introduced, LVAD recipients roughly had a 50% [6] one year survival rate, however
this has changed in recent years with subsequent generations of the devices. Current
LVAD models have shown to have one year survival rates of 80%, which is nearly that
of orthotopic heart transplant, 86% [6], the historically optimal treatment. There
is a desire for LVADs to become terminal treatments rather than bridge to surgery
treatments, however in order to do so select short-term issues must be mitigated or
resolved.

1.1
1.1.1

Background
Circulatory/Thoracic System

The human circulatory system is the primary organ system responsible for the circulation of blood throughout the body along with varied nutrients, organic elements,
17

etc. In its essential role, oxygenated blood is transported from the heart to significant tissues and bones, while the subsequent deoxygenated blood is returned to the
heart for re-oxygenation. To accomplish this process the circulatory system is comprised of several key components, each with unique physiological characteristics and
subprocesses. For purposes of this work, the lymphatic subsystem of the circulatory
system is not considered. In accomplishing its primary functions, as it pertains to
this research, the system’s integral components are the heart, the circulatory vessels
(veins and arteries), and blood.
Of particular interest for this work is the architecture and cyclical function of the
heart, as it is the organ responsible for the pulsatile flow of the circulatory system.
The human heart is comprised of four chambers, two atria and two ventricle, along
with four major valves. All components function in a joint process producing the
cardiac cycle, or the pseudo-periodic process of the heart. The three most significant
phases of which are atrial systole, ventricular systole, and cardiac diastole (atrial and
ventricular diastole lumped together). Systole and diastole can be considered inverse
processes of each other. When in systole the heart contracts, ejecting blood from the
respective chambers. Alternatively, when in diastole the heart tissues relax allowing
blood to re-enter the heart. In terms of progression diastole is the first stage, followed
by atrial systole, and finally ventricular systole, however ventricular systole and atrial
diastole overlap to where they can be assumed to occur concurrently or continuously.
In order to prevent a continuous process (lack of distinct phase) the four heart
valves function in accordance with the phase to control blood flow (Note Figure
1-1 for architecture). When in diastole both the aortic and pulmonary valves close,
preventing ejection, while the tricuspid and mitral valves open intaking blood. During
atrial systole the tricuspid and mitral valves open, sending blood from the atria to the
ventricles. Finally, during ventricular systole the tricuspid and mitral valves close,
while the pulmonary and aortic valves open circulating blood from the right and left
ventricle to the pulmonary artery and aorta respectively.
The systolic and diastolic phases of the heart cycle are of significant importance
as they are directly related to heart sounds. Heart sounds are those sounds produced
18

Figure 1-1: Human heart cross-section [8].
as a result of the fluid (blood) turbulence generated from the opening and closing
of the heart valves. In most healthy individuals only the first two heart sounds are
prevalent, the S1 and S2 sounds. However, in other individuals the remaining two
sounds, the S3 and/or S4 sounds may manifest, with the potential for other sounds
such as murmurs.
Both the S1 and S2 originate from closing valves, and specifically align with the
cardiac phase. The S1 is caused by the initial systolic contraction, or the closing of
the tricuspid and mitral valves. The S2 is the result of the end of systole, or rather
the closing of the aortic and pulmonary valves caused by cardiac tissue relaxation.
The S1 and S2 are more so referred to as the "normal" heart sounds as both the S3
and S4 are indicative of health issues such as congestive heart failure and systemic
hypertension respectively. It should also be noted that the presence of the S3 or S4
is not the sole indicator of health/condition. Referring to Figure 1-2, many of the
more commonly seen conditions (stenosis - narrowing of vessel area; regurgitation 19

Figure 1-2: Heart sounds of varied health conditions [17].
leakage from a valve upon relaxation) do not manifest as either the S3 or the S4.
They are instead more typically characterized by completely different sounds, and
often perturb and alter how the S1 and S2 occur and appear.

1.1.2

Left Ventricular Assist Devices

The S3 sound, being an indicator of congestive heart failure (CHF), is caused by ventricle overload. Left ventricle overload, or more generally systemic volume overload,
is the heart condition in which the left ventricle is not strong enough to eject an
adequate (55% or more) blood volume resulting in suboptimal circulation. In mild
cases CHF can be treated with angiotensin converting enzyme (ACE) inhibitors and
20

angiotension receptor blockers (ARBs) among others, however in more severe cases
the historical optimal proceedure has been orthotopic surgery [20].
Since the initial REMATCH trial of 2002 [20] left ventricular assist devices (LVADs)
have been used as a bridge to surgery option for patients awaiting orthotopic surgery.
These devices graft from the left ventricle to the aorta (Figure 1-3) acting as a pump,
i.e. increasing circulation and thus compensating for CHF and/or the related issues
(coronary artery disease, etc.). While the LVAD itself is internally contained within
the thoracic cavity the controlling unit and power supply are housed externally of the
patient.
Assuming the optimal mean arterial pressure (MAP - systolic aortic pressure over
diastolic aortic pressure) is 110/70 mmHg, a 40 mmHg blood pressure range is considered ideal. Patients who suffer from CHF or similar do not exhibit these same
characteristics. They are more likely hypertensive (high blood pressure) or hypotensive (low blood pressure), deviating from the optimal MAP range. Approximately
90% of LVADs [6] are continuously driven, meaning that they operate at fixed speeds
and do not pulsate. The physiological effect of this, in terms of MAP, is a reduction
in range that roughly scales with speed (Figure 1-4). Upon increasing the influence of
the LVAD (i.e. increasing speed) the MAP range is decreased, theoretically approach-

Figure 1-3: LVAD graft diagram [4].
21

ing a constant pressure (no difference depending on systolic and diastolic phase). Of
particular importance is the realization that the electrocardiogram (EKG) signal of
an LVAD patient is unaltered by the device. The EKG can be leveraged as a high
fidelity signal for identifying phase and cycle when the MAP cannot be, due to the
previously mentioned LVAD dynamics.

Figure 1-4: ECG, respiration (Resp), finger blood pressure (FBP), and muscle sympathetic nerve activity (MSNA) tracings for 1 patient at baseline (top) and at 3200
rpm LVAD speed (bottom) [23].
22

1.2

Need for Research

Since the REMATCH trials LVADs have become increasingly common and practical.
When first approved (2001) LVAD patient one year mortality rates were roughly 50%
[6] while two year survival rates were just 28% [21]. As of 2016 one year survival rates
have improved to 80%, just short of the orthotopic surgery survival rate (86%). The
notable improvement in patient survival can be attributed to several factors such as
improved designs [2] and diagnostic capability advancements concerning both VADs
and related thoracic implants [13],[9] among other factors.
Regardless of short-term viabilty, LVAD long-term practicality remains a considerable issue for several reasons. Even thought two year survival rates of 76% have
been reported [12] these numbers are heavily skewed by extraneous factors. The
patients from this test sample were originally of the lowest risk. Under a more representative sample this rate would be expected to decrease. Additionally, these patients
were treated post-opt (regular anticoagulation therapy and routine in-patient management), as is typical with implantees. This further complicates the reported figures
as varied treatments (anticoagulation) have counterintuitive adverse effects on health,
predisposing patients to increased likelihoods of issues such as bleeding. These issues
are less device orientated, and so one must further make the distinction between
mortality and device related mortality.
Patient mortality is attributed to a wide range of issues steming from the instance
of surgery as alluded to previously. The key categorical complications of implantation are bleeding, thromboembolic events, infection, aortic insufficiency, and right
ventricular failure [5]. This work focuses solely on thrombosis based events, which
also extends to device graft stenosis. In more general terminology, thrombosis and
stenosis based events may be classified as occlusion events.
Thrombosis is the condition in which a blood clot locally develops in the circulatory system, in either a vein (venous thrombosis) or artery (arterial thrombosis).
Arterial occlusion (blockage) can be a result of either direct thrombosis formation or
arterial embolism (event in which a clot "breaks off" and travels downstream). Direct
23

thrombosis formulation is due to local coagulation as a result of atheroma (fatty deposit on the internal vessel wall) rupture. Arterial embolism however may be a result
of cardiogenic (originating from the heart) clots. For purposes of this work arterial
thrombosis will be focused on, as venous thrombosis is not localized to the immediate
area of the heart.
Due to the range of LVADs approved for use, biocompatability is not guaranteed [24] and so thrombosis has been and continues to be an issue for implantees,
especially at the location of the device, particularly the outlet stators. Older LVAD
models, being larger, tend to produce embolisms while newer, smaller models lead to
hemolysis (red blood cell destruction), although thrombosis may still occur. Thrombosis of newer LVADs (continuous models - previously stated 90% implantee population usage) is dependent on several parameters involving the patient, clinician,
and the device itself. Specifically speaking to pump thrombosis events (exclusive of
graft thromboembolic events) the frequency of such events have been reported to
be in the range of 1-4% of test patients with a HeartMate II (continuous flow axial
model) and in the range of 2-8% for HeartWare (continuous flow centrigual model)
[19] patients. Even with anticoagulation treatments, under-anticoagulation remains
an issue for patients. Protocol for such treatment is dependent on the individual clinician/institution and so a universal and robust procedure does not exist for mitigation
of thromboembolic events, aside from LVAD replacement in severe cases. Clearly,
widespread and complete remediation of thromboembolic events is not short-term
plausible given the current state of the issue.
Current diagnostics of adverse LVAD conditions are not restricted to any singular
means. Both clinician laboratory testing and diagnostic imaging methods have been
shown to indicate varied conditions [24]. Specifically, with respect to thromboembolic
events, transthoracic (TTE) echocardiography (TTE), transesophageal echocardiography (TEE), and computed tomography angiography (CTA) are the most important
imaging diagnostic methods. Both TTE and TEE can be specifically used for thrombosis diagnoses while CTA is more so complimentarily used in diagnosing outlet flow
mechanical problems, when indicated based on echocardiography.
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Figure 1-5: LVAD diagnostics methods for determining localized fault area [24].
Even though diagnostic methods do exist for discerning device condition and
events, determining the exact localization of the issue is more difficult (Figure 15). Echocardiography and CTA can be used for examining both the inlet and outlet
grafts, with specific caveats requiring direct examination (invasive operation) such
as the extracardiac portion of the inlet graft. While imaging is appropriate for the
implant graft, examining the LVAD itself cannot be done with such, requiring direct
examination, which is problematic for stator thrombosis/occlusion. A combination
of laboratory testing and imaging can be robustly used to identify general conditions, however it is evident that localization identification, especially concerning the
areas requiring invasive procedures, is not optimal. It would instead be of great value
and importance to develop a robust and more practical method for the noninvasive
discernment of occlusion localization.

1.3

Proposed Methodology

To discern an LVAD patient's health a signal containing the key indicator/s of their
condition must first be identified. The goal of noninvasively collecting the identifica25

tion signal limits the potential collection methods. Furthermore, the innate variation
in physical and biological traits [3], as well as implanted device types does not support the practice of creating a universal baseline for condition evaluation, practically
speaking. In fact a common diagnostic method using TEE [24] requires baselining
the individual patient post initial surgery.
It has been widely accepted that thoracic sounds, or rather more specifically heart
sounds, correlate to specific health conditions (Figure 1-2). Given this correlation,
it can be extrapolated that a device modified thoracic environment will exhibit the
same relationship, to some degree. Various authors have verified this theory with
regards to both VAD specific devices and to general thoracic implants. Masson et
al [14] showed that artificial heart acoustics can be used to determine prosthetic
valve operation, and correlated the sound to physiological occurrences. Makino et
al [13] proved that artifical heart acoustics are relative to lifespan, in that there is a
relationship between the produced acoustics and physical condition of the artificial
heart pump. Whereas Makino et al focused on variable condition, Kim at el [9]
showed that the same acoustic signal could be used to discern early stage device
failure. Yost et al [28] showed that LVAD specific thromboembolic events manifest
in the frequency spectrum of the thoracic acoustics. Slaughter et al [20] confirmed
Yost’s findings and expanded the work to include mechanical failures. Kaufmann et
al [7] studied the acoustics of centrifugal VADs, and found that regardless of VAD
design (axial/centrifugal) events and conditions manifest in the produced acoustics
in a similar manner. Thoracic acoustics have been proved by several authors to be a
viable signal in preforming diagnostics, specific regarding the cardiac system/cardiac
implants.
The purpose of this work is to determine a viable and noninvasive method for diagnosing LVAD related health issues, specifically outlet graft occulsion, or thrombolic
events. To do so in vitro (artificial) heart sounds are simulated (mimicked) using a
one sided (left) heart chamber simulator which simulates circulatory system characteristics and behaviors. The right side is not included as the LVAD device boundary
conditions only pertain to left side and terminal components (left ventricle and aorta).
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Acquiring the acoustics from this setup is performed using a digital stethoscope. Various authors have previously used electronic stethoscopes for the exact purpose of
acquiring thoracic acoustics [22] for post-processing and have shown that the devices
are appropriate for LVAD modified cavities as well [13],[28].
In order to determine the effects of physiological state variation (blood pressure
and heart rate) both the healthy and unhealthy system (manually faulted) are operated over a non-hypotensive and non-hypertensive region for all test iterations. The
process frequency of the simulator (akin to heart rate) is similarly modulated for
specific diagnostic determinations. Testing occurs at both constant heart rate and
variable heart rate. Outlet thrombolic events are simulated through seeded-fault testing, wherein a blockage is inserted downline of the LVAD in the simulated system and
the system is operated as if it were healthy, i.e. still in the non-hypo/hypertensive
region. The resulting in vitro acoustics are compared against similar in vivo acoustics
to confirm mimic validity.
Once collected, the audio signals are post-processed for classification, to determine diagnostic potential. Due to the non-stationarity of natural heart sounds more
traditional frequency spectrum techniques such as the Fourier transform are not appropriate. Time-frequency techniques that enable the specific identification of spectra
events are much more practical for use [1],[27], however a suitable resolution must
be attained [15]. Alternatively, the greater the resolution of the technique the more
resource intensive the technique is. There is a clear desired to manage the trade-off
between resolution and computational resources especially when concerning potential
embedded processor application. As such this work focuses on utilizes the continuous
wavelet transform (CWT) as means of determining time-frequency representations
(spectra) of both the in vitro and in vivo acoustics. The CWT is a multi-resolution
technique that leverages increased processing cost to produce improved resolution
over techniques such as the short time Fourier transform (STFT). The technique is
modified to maintain minimal computational cost for this work.
Resolution is an important factor in the diagnostic process as one would expect
that the component of the derived spectra that indicates a specific condition is not
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necessarily consistent in occurrence. Rather the indicator is expected to manifest in
specific regions or frames, regarding the time-frequency plane. Under this assumption
it is beneficial to only examine those locations, or regions of interests (ROIs). Doing so
reduces dilution of the indicators caused by spectra regions of no discernible impact or
importance and increases overall processing efficiency. Similarly, should an indicator
manifest in a specific phase, limiting the spectra to said phase will decrease bias and
warping caused by the adjacent phase.
The resulting ROI spectra can now be examined to identify discrete metrics used
in evaluating patient condition. This is done so by generating a series of identification
features from derived images of the ROI spectra. These identification features range
from grayscale image texture properties to binary (black and white) shape features.
Rather than just operating on the raw complex spectra matrix, this process of reducing down through images allows for a more systematic control of identification feature
production.
The resulting identification feature vector, a 31x1 array of discrete image parameters, therein contains the desired indicator/s. Although this is true, the most optimal
combination of these values is not known a-priori, assuming some features have no
significance, are redundant, etc. Additionally, this dimensional space cannot be visualized in order to discern feature weighting, making the identification process difficult.
A support vector machine (SVM) is trained with the a specific set of the feature vectors to develop the classifier model. This model is then used in determining the class
(condition) of an independent set of testing data. Several different training-testing
iterations are performed, utilizing both the constant heart rate acoustics along with
variable heart rate acoustics.
Chapter 2 details the process of generating and acquiring the audio signals of the
in vitro simulator and compares them to the related in vivo trials. This includes
verification of the correlation between the generated in vitro acoustics and the physiological in vivo signals. Chapter 3 provides the theory and methodology for the
post-processing of the acquired data. Cycle decomposition, time-frequency spectra
generation, ROI partitioning, and feature composition are covered. Chapter 4 pro28

Figure 1-6: Flow chart of research methodology.
vides classifier information and the results of the respective trials. In Chapter 5 the
conclusion of this work is given along with the next steps to be taken to advance this
work. A guide of the process performed in this work is given in Figure 1-6.
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Chapter 2
Data Generation and Acquisition
The sounds produced by the human heart are complex acoustic signals with shown
correlations and causalities to physical events (Figure 1-2). Additionally, the location
and medium through which the signals, which are essentially vibrations, propogate
significantly affect the observable signal [3] and the ability to accurately measure said
signal. The process by which a synthetic biological component is created is called
mimicking, or phantoming, with the resulting component being termed the phantom.
For purposes of this work, the in vitro simulator is an active phantom, in that it
both produces the objective signal (heart analogy) and passively transmits it (soft
tissue, fat, etc.). For the in vivo trials phantom components are not necessary, however it is necessary to acknowledge the innate variations between both patients and
controlled trials, and how they correlate and/or deviate from each other.

2.1
2.1.1

In Vitro Generation and Acquisition
Cardiac Phantom

Artificially generating heart sounds is non-trivial due to the non-stationarity nature
of the signals. Non-stationarity is the term used to define the characteristics of the
acoustic signal generating process, specifically as it pertains to the cyclical nature of
the heart sounds. In this context (non-mathematical, will later be defined in more
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appropriate terms) non-stationary defines the variability of the sounds. If a process
were stationary it would be perfectly cyclical, or rather it would be predictable. A
non-stationary process would then be defined as one that is not entirely predictable,
or requires more information to describe/quantify. Heart sounds are considered nonstationary events for several observable reasons (among others),
1. Valvular (S1 and S2) and non-valvular (S3 and S4) occurrences
2. Variable heart rate
3. Discrete loading perturbations produced by valvular activity (S1 and S2 variation) [27]
The non-stationarity of the physiological process is due to the nervous system’s
modulation of purkinje fibers, which enable instance synchronized ventricular contraction. Fiber contraction is not modulated over intervals, rather at each individual
heartbeat, thus the process is not stationary. In short and controlled intervals, heart
cycles can be considered pseudo-stationary, however in general this not true, notably
when the duration and timing of events (S1, S2, etc.) are not consistent.
From a biological definition, the electrocardiography (EKG) signal is the measure
of the electrical signals propagating through the heart, due to cardiac muscle depolarization (loss of net charge across the muscular membrane). The four de/polarization
intervals (Figure 2-1) or waves (P - atrial depolarization, QRS complex - ventricular
depolarization, T - ventricular repolarization, and U - Purkinje repolarization. U
wave not shown in Figure 2-1 as it is intermittently observed and often discussed as
a parameter lumped with the T wave) occur concurrently with cardiac phase, rather
than pulse which occurs as a post-product. The QRS complex interval of the EKG
signal is of the most importance for this work. The QRS complex indicates not only
ventricular depolarization, but also ventricular systole (repolarization equating to systole, while depolarization equating to diastole), meaning that the peak magnitude of
the QRS relates to a process event. The QRS is the greatest magnitude component of
the EKG, and so generally speaking the heart cycle process can be initially referenced
relative to the interval maximum of the EKG, the R wave.
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Figure 2-1: Wiggers diagram of idealized healthy left heart chamber performance
synchronized to EKG propagation [10].
As stated EKG propagation and cardiac phase are concurrent processes. In actuality cardiac phase is the causality of EKG propagation, however this assumedly
does not cause a significant time varying phase difference. As this is assumed, then
it follows that the inverse holds true for phantoming, specifically a synthetic EKG
may be used to modulate cardiac phase without significant phase effects. It can
then be stated that the specific cardiac phases can be modulated through specific
intervals/events of the synthetic EKG.
While the local maxima of the EKG relates to the timing of ventricular systole,
no analogous minima - diastole relationship exists. The T wave interval of the signal identifies ventricular diastole, however identifying this component is less obvious
than that of the QRS complex. In a similar sense, while generating an EKG signal
indicative of the physiological signal is not difficult, practically implementing such
with the phantom is difficult. This is due to the increased need in control surfaces
and components. Rather, to simplify the phantom design it is assumed that atrial
systole occurs concurrently with ventricular diastole and that atrial diastole occurs
concurrently with ventricular systole. Doing so reduces the cardiac cycle to two generalized intervals, ventricular systole (atrial diastole) and ventricular diastole (atrial
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systole). The EKG accordingly reduces down by one interval. It should also be noted
here that the U wave of the EKG is a manifestation of ventricular repolarization
as well, and so both the U and T waves can be practically combined. Making the
above generalizations yields an EKG signal of two distinct intervals, the same as the
approximated cardiac cycle.
The EKG maxima (QRS complex maxima) is preserved from the above theory,
while the remaining waves are lumped into a new interval relating to ventricular
diastole. The new interval can then be created in such a way to initiate diastole,
with the obvious choice being to generate a specific minima to time the phase. If
a phantom is chosen to modulate phase based on only the locations of the maxima
and minima then any alternating signal is adequate. Thus any finite closed bounded
alternating signal may be used to modulate phase, with the simplest choice being an
alternating ramp signal. The slope of the ramp (+/-) denotes cardiac phase and the
maxima and minima location control phase duration.
The ramp input that modulates cardiac phase for the developed phantom is generated using an Instek function generator. Doing so limits the phase duration split
to 50/50 however allows for easy control of the simulated phase period, and thus the
process frequency (simulated heart rate). The downside to this application method
is the loss of non-stationary elements, namely heartbeat-to-heartbeat variable frequency (unless manually modulated as such) and variable event occurrences (signal
variation). The generated signal is then used to modulate a compressed air controller,
which ports to the ventricle phantoms.
The ventricle phantom (Figure 2-2) is comprised of a hollow flexible polymer
encased in an air-tight metal-plastic shell. The polymer acts as the ventricle itself,
in terms of functionality, while the shell is the component which regulates the shape
of the polymer. The shell is pressurized using the external air supply ported through
the back of the phantom. When the pressure of the shell is greater than that of the
polymer it forces the polymer to constrict (ventricular systole). When the pressure
of the polymer is greater than that of the shell, the polymer expands (ventricular
diastole) (Figure 2-3).
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Figure 2-2: Ventricle phantom. Right: Side View | Left: Top View

When the polymer is filled with liquid, constriction causes the ventricle to purge
the liquid, while relaxation allows liquid to re-enter the polymer. The polymer has
three openings that permit fluidic movement, an inlet pathway, an outlet pathway,
and a backend pathway. Without unidirectional valves, all three openings permit

Figure 2-3: Ventricle phantom during cardiac phase change.
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multidirectional flow. The inlet and outlet paths are used to interface the phantom
with the atrial and aortic pathways respectively. The backend path (at the rear) of
the phantom, is used as the inlet to the VAD graft, but is otherwise sealed should
there be no VAD implemented.
The pressure difference between the polymer and shell modulates the phase propagation rate (the rate at which the ventricle phantom compresses/expands) of the
phantom. The compressed air controller pressurizes (Figure 2-4) the shell through
the air port on the back of the shell. The controller itself receives air through a
facility main (>100 psi), which is regulated down to 40 psi (so that the controller
can bleed off excess pressure). The timing of the controller is modulated by the
synthetic EKG. The magnitude of the pressure is controlled via analog controls on
the controller front panel. Systolic pressure can be regulated from 0 mmHg to 300
mmHg, however diastolic pressure is a fixed 0 mmHg. The fixed diastolic pressure is
not an issue as physiological ventricular diastolic pressure is approximately 0 mmHg.
As previously stated phase is arbitrarily split 50/50, however the exact duration of

Figure 2-4: Compressed air controller used to regulate ventricular phase of the phantom.
36

the active compression/expansion transient is related to the pressure difference of the
polymer-shell. This is the most significant shortcoming of the simulator. Due to only
modulation of the phase triggering, propagation of systole and diastole are entirely
dependent on the pressure gradients of the simulator. Due to the lack of control there
is no guarantee that the ventricle will entirely expand/contract for a given pressure,
heart rate setting, an issue that will be examined in Section 2.3.
Using the function generator, air controller, and ventricle phantom systolic and
diastolic ventricular phase are mimicked. The characteristics of the generated cycle
however do not yet correlate to that of the physiological cycle, specifically in terms
of pressure and flow. Given that fluids across a control volume cannot travel to
passively produce a positive gradient, it is assumed that if the pressure conditions
for the phantom are met, then the flow conditions will be suitable met. Additionally,
flow is not a direct boundary condition relating to VADs, thus not requiring further
attention. Instead the ratio of uncompensated flow (No VAD) to compensated flow
(with VAD) is more practical to use in examining the fidelity of the phantom although
neither are of significant importance for this work.
The idealized model of the physiological cardiac cycle is the Wiggers diagram
given in Figure 2-1. While used to describe the healthy (no VAD/illness) three phase
cardiac cycle (lumping repolarizations), it can similarly be used to describe the approximated two phase cycle. Additionally, the Wiggers diagram only describes left
chamber characteristics and functions, making it pertinent for achieving the desired
phantom architecture. As previously stated, the ability to mimic phase is already
achieved, leaving only the pressure states to be met.
Valvular events are known to be the source of the predominant healthy heart
sounds (S1 and S2) due to the fluidic turbulence generated as a result of the events.
As expected, the valves are the physiological elements that maintain circulatory unidirectional flow. The need for such elements is apparent when examining points of the
cardiac cycle in which the downstream pressure is greater than that of the upstream
pressure. An example of this occurrence is during diastole, when aortic pressure is
greater than left ventricular pressure, or during systole when ventricular pressure is
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Figure 2-5: Positioning of bileaflet valves at the inlet and outlet of the ventricle
phantom with resulting unidirectional flow indicated by red dotted lines.
greater than atrial pressure. When such is true the heart’s valves change orientation,
preventing backflow. In order to mimic this in the phantom, a set of bileaflet valves
are implanted prior to and post to the ventricle element.
Bileaflet valves are a traditional prosthetic used in cardiovascular operations that
offer low resistance to flow. One valve is positioned prior to the ventricle phantom
(after the atrium) and is orientated in such a way as to close should ventricular
pressure exceed atrial pressure (Figure 2-5). Similarly, the other valve is positioned
after the ventricle (before the aorta) and is orientated in such a way as to close should
the aortic pressure exceed ventricular pressure. Bileaflet valves do have a slight delay
in changing orientation, resulting in a small amount of backflow during the event
transient, however is assumed to be negligible as flow will be significantly skewed to
one direction over the entire cardiac cycle. Additionally, this delay is affected by the
pressure difference across the valve, and so with given specific pressure differentials
the valve lag may be insignificant.
The last parameter to achieve with the system phantom is aortic pressure. Due
to the effects of the valves systolic aortic pressure is regulated by systolic ventricular
pressure. During compression, ventricular pressure spikes causing a pressure equal38

ization across the aortic valve. The valve opens, resulting in aortic pressure tracking
ventricular pressure. During late systole ventricular pressure begins to drop, at a similar rate of the previous spike. Due to this rapid change, ventricular pressure drops
below aortic pressure causing the aortic valve to close, thus maintaining diastolic
pressure as the valve orientation prevents equalization.
Controlling diastolic pressure requires controlling the point at which the aortic
valve changes orientation. To do so the pressure difference across the valve must
be changed in such a way to elicit valvular activity. The pressure at the interior
(ventricle side) of the valve is approximately set by ventricular pressure leaving the
exterior pressure (aortic pressure) as the sole controllable parameter. In order to alter
the aortic pressure of the system a pipe clamp is used (Figure 2-6) to restrict system
flow, thus increasing the induced aortic pressure, at the external side (aorta side) of
the valve. The inclusion of the valve gives the ability to alter the aortic pressure of the
closed loop system to varying degrees based on how restrictive the clamp orientation
is (more restrictive yields greater aortic pressure).
A capacitive element is added to the backend of the clamp to allow for (Figure 2-6)
control over atrial pressure. The capacitive element is a fluid retaining vessel which
is open to ambient. The vessel is not pressurized for two key reasons: 1) Ambient
serves as a consistent backend pressure basis for the system/clamp 2) At the other
adjacent end of the vessel is the left atria component (closed system design) which
cycles significantly closer to zero than ventricular pressure. By having an element near
the atrium component base at zero (vent to ambient) it can be ensured that diastolic
atrial pressure roughly minimums at zero while systolic atrial pressure is minimally
affected by ventricular pressure (early rising ventricular pressure will result in a large
pressure gradient across the mitral bileaflet valve, causing the valve to close, limiting
the maximum of the atrial pressure).
In the prescribed architecture, the aortic pressure is regulated, then vented to
ambient before recirculation to the atria. This design however neglects all non-heart
local physiological components (blood vessels, arteries, capillaries, etc.) that otherwise affect blood flow, of particular importance concerning the left heart chambers.
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Figure 2-6: Simulator capacitive and resistive elements used in mimicking compliance
and regulating aortic pressure.
Circulatory system resistance, as a generalized and lumped parameter, is inherently
incorporated by way of the clamp, however biological compliance is not. Compliance
is essentially the elasticity of hollow organs, particularly for this work, circulatory
vessels. Compliance is the factor by which a vessel or artery will change volumetrically in response to a change in pressure. Due to the pressure changes that occur as
a result of cardiac phase, circulatory compliance is an important factor as it pertains
to both observable blood pressure and to regulation/control of the simulator.
Modeling circulatory system compliance, in a non-generalized model, is not practical as compliance is not localized. It is dependent on several factors such as tissue
type, circulatory system location, and health, among others. It is however known that
blood vessel compliance is significantly higher than arterial compliance, specifically
by a factor of as much as 30. Being the case a singular phantom element suffices for
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Figure 2-7: Phase effects on compliant element, mimicking venous and arterial elasticity.
incorporating both vessel and arterial compliance factors.
A compliant phantoming element is integrated into the system, using the same
fluid retaining vessel as used previously with the post-clamp venting element (Figure
2-6). The element is positioned prior to the clamp in the loop (post aortic valve), so
that compliancy can be generated from fluid compressibility (Figure 2-7). Whereas
compliancy is a quantification of solid elasticity based on pressure differentials, compressibility is essentially a fluid analogous parameter. An arbitrary compliant factor
can be integrated by means of a compressible fluid volume within the vessel, specifically an air pocket. This air pocket compresses upon systolic phase, and respectively
decompresses during diastolic phase, mimicking circulatory compliance. Exact control over the parameter is not feasible as the system is barometrically vented, and so
any desired pressurization is altered by the venting boundary. Instead the relative
degree of compliance is used to alter system pressure. As the ratio of air to water in
the compliant element is decreased (increasing water level) greater pressure states are
41

achievable, with the pressure state defined as the mean arterial pressure (MAP) or
systolic pressure over diastolic pressure. Conversely, as more air is added to the compliant element, the feasible MAP range decreases. Thus by controlling the relative
compliance effect, a wide range of pressure states are able to be simulated.

2.1.2

Acquisition and Seeded-Fault Testing

The cardiac system phantom (Figure 2-8) is probed at several locations to acquire
four core measurements, the synthetic EKG (trigger), ventricular pressure, aortic
pressure, and system flow. All four are acquired using an NI USB-6212 module and
are sampled at 10 kHz. The trigger function is directly split into the module from
the function generator. System flow is acquired using a Transonic Emtec ultrasound
flow sensor located prior to the compliance vessel (post aorta, pre-vessel). Ventricular
pressure is probed at the face of the ventricle phantom, while aortic pressure is probed

Figure 2-8: Component annotated in vitro simulator without VAD implemented.
Dashed red lines indicate flow direction through system.
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at a tee connection (for purposes of including VAD graft line) post aortic valve, precompliance element. Both pressure measurements are acquired using TDH40 pressure
transducers. These four parameters are used only for referencing system state and are
not used in any significant post-processing algorithm, other than the trigger. Given
this the resolution of the signals is not scrutinized.
Comparing the in vitro generated pressures (Figure 2-9) to the Wiggers model
(Figure 2-1), the only relatively significant difference occurs during ventricular diastole, when ventricular pressure does not minimum to zero mmHg. This occurrence is
a by-product of increasing system resistance to meet aortic pressure conditions and is
unavoidable. It should also be noted that for the presented iteration (Figure 2-9) the
system was tuned to an approximate mean arterial pressure (MAP) of 110/70 rather
than the Wiggers MAP of 120/80. This is of no significance; it is simply presented to
show the fidelity of the simulator, respective to the idealized model (Wiggers model).
Oscillations in pressure (Figure 2-9) are a result of both system compliance and
transducer interface compliance. The transducers measure fluid pressure at the face

Figure 2-9: In vitro simulator pressure curves at a heart rate of 57 BPM.
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of the device, which under stationary conditions (non-pulsating) would not require
interfacing compliance. Due to both the pressure spikes caused by alternating phase
and bileaflet valve delay, the fluid surface at the face of the transducers are not in
constant contact with the transducer. Bileaflet valves are previously discussed to
permit a small amount of backflow due to their inherent delay in changing orientation. During this delay, the pressure differential across the valve propagates to the
transducer face. Specifically, during diastole the fluid at the face is pulled away during the delay interval, causing an intermittent vacuum at the transducer face. This
occurrence is an unfortunate by-product of the transducer arrangement, and so the
transducer interface is modified as to maintain constant contact. This is done so by
slightly pressurizing the transducer line prior to filling the in vitro system, creating
an air pocket at the transducer face. During systole and diastole, the system fluid
will force the air pocket to compress and expand respectively, however during both
phases, due to gaseous properties, the transducer face will remain in fluidic contact preventing intermittent vacuuming. Both transducers are arranged as such for consistency, which is the reason for the non-zero diastolic ventricular pressure shown in
Figure 2-9.
Acquiring phantom acoustics is less trivial due to the measurement surface and
location having a significant effect on the observed signal. Given the system shown in
Figure 2-8 there is no appropriate location for probing with a stethoscope diaphragm.
The system lacks both a flat surface and the appropriate transmission phantom (i.e.
soft tissue). Similarly, the positioning of the VAD needs to be considered in advance.
Left ventricular assist devices require two graft surfaces, the left ventricle (inlet)
and aorta (outlet). The ventricle phantom includes three connection surfaces (Figure
2-2), the front two being used for inlet and outlet flow, and the backend surface
which is the location of the VAD inlet graft. The VAD outlet graft connects to
the tee connection where the aortic pressure is probed, completing the VAD graft
loop of the system phantom (Figure 2-10). For accomplishing seeded-fault testing
an additional blockage element is inserted into the loop, prior to the tee connection,
simulating an outlet graft occlusion.
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Figure 2-10: Component annotated in vitro simulator with VAD implemented.
Dashed red lines indicate flow direction through system. Note that the purge line
is used only for draining the system.

The blockage element is comprised of two individual pieces, one containing the
physical blockage surface, while the other acts as both a housing for the blockage piece,
and provides a flat instrumentation surface for a stethoscope diaphragm. The element
is designed with several flat surfaces, however acoustics are acquired at only one
surface, the top most for consistent weighting. Using this component, two different
levels of occlusion are implemented, 0% and 75%.
The stethoscope used for acoustic collection is a ThinkLabs Digital One stethoscope (Figure 2-11). Unlike other piezo-electro sensor based digital stethoscopes,
the Digital One utilizes a capacitive sensor, which offers comparatively improved
performance capabilities [11] due to improved signal magnification/resolution. The
stethoscope has several preset filter notches (depending on practical use wants) and
amplifications levels. For all test iterations the stethoscope is used in wideband (20
hz - 2000 hz bandpass) filter mode at a sound amplification level of 7. The filter mode
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Figure 2-11: Occlusion element placed in VAD loop with stethoscope placement
shown.
is chosen as to not filter out any potentially pertinent signal components, while the
amplification level was chosen heuristically based on acoustic properties and trends
found in preliminary results. The upper filter band of 2000 hz, while not optimally
chosen, is suitable as the HeartMate 2 does not operate in a regime in excess of 20000
RPM (330 Hz) nor do heart sounds significantly manifest in high frequency bands
(1000 Hz).
The thoracic cavity is a very non-homogenous region of the body. In terms of cardiac ascultation, the are four predominant locations for listening to valvular sound,
of which all are intercoastal spaces (Figure 2-12), composed of different dermal and
internal tissues, structures, etc. Additionally, listening to VAD noises may require
probing non-typical auscultation sites, such as the subcostal region or anterior axillary line. Without a full cavity phantom with varying compositions, creating an
physiologically inclusive tissue phantom is impossible. Instead, it is more appropriate
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Figure 2-12: Locations of stethoscope placement for auscultation of valvular heart
sounds [24].
to develop a consistent and replicable tissue phantom [3] that can be consistently used
across iterations. Yost et al [28] previously used a silicone based molding, EcoFlex
00-10, to develop a soft tissue phantom for transmitting VAD acoustics to a stethoscope. The molding material was previously documented to have properties similar
to soft tissue, and thus is chosen as the soft tissue mimic for this work.
In their work Yost et al set a HeartMate 2 VAD into a block of EcoFlex, with 3 cm
of material separating the VAD to the outside surface of the silicone, asserting that
this thickness mimics physiological soft tissue acoustic transmission. In this work
acoustics are acquired at both the obstruction site (Figure 2-11) and at the VAD
surface, with the obstruction site being the primary focus. The obstruction site is
chosen as it makes logical sense to directly probe at the expected fault location, as
it would manifest most directly there. To facilitate transmission at the obstruction
site a 1.5 cm block of EcoFlex is used as the transmission phantom. The material
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thickness was reduced from Yost’s application due to the blockage structure transmission properties. The properties of the component are unknown, and so it is assumed
that using a 3 cm silicone thickness results in overly attenuated signals, and so the
thickness is arbitrarily cut in half. The physical parameters of the material are not as
important as is consistent use of the phantom. When probing at the VAD surface, a
2.8 cm thick molding of EcoFlex is layered over the VAD, in an attempted to replicate
Yost et al’s experimental setup.
Without a VAD implemented into the system systolic ventricular pressure strongly
matches systolic aortic pressure (Figure 2-9), as by design. Diastolic pressures are
correlated to a significantly lesser degree, however a general direct trend does exist (increasing system resistance results in increased aortic and ventricular diastolic
pressures). The inclusion of a VAD into the system (Figure 2-13) does not eliminate
these trends, however the degrees to which they occur are decreased as a result of
the additional circulation resulting from the device. To achieve a similar ’non-VAD’
MAP, ventricular pressure and resistance must be decreased, resulting in a diastolic
ventricular pressure aligning more closely to zero. Systolic pressures now exhibit a
positive offset due to the additional head resulting from the LVAD.
Using the simulator various ranges of boundary condition pressures and heart rates
are simulated, with the healthy range of such isndefined by the non-hypertension and
non-hypotension (systolic pressure in the range of 130-90 mmHg, diastolic pressure
in the range of 80-60 mmHg) region of MAP. For all tests this region is referenced as
the healthy mean arterial pressure region (HMAPR). With the LVAD incorporated
into the system the boundary conditions must change such that the resulting MAP
is in the HMAPR, rather than the boundary conditions. Of course this is generally
speaking as it is shown by Tank et al [23] that device speed affects the resulting
MAP and may induce hypo/hypertension pressures. As such the HMAPR is used as
a general guide with the intent of maintaining the majority of tests into this region,
however this is not a hard constraint. Tests within a +- 10 mmHg of MAP are
simulated to be inclusive of the occurrence shown [23].
Tests are run in 15 second increments at the previously specified sampling rate of
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10 kHz. The state of the test is defined by the average MAP over that interval along
with the average heart rate of the acquisition interval. The specific MAP setting
is kept constant over the test interval however heart rate is modulated to be either
constant or variable. Tests are run at these specific rates for reasons detailed in
following chapters as each condition requires different post-processing operations and
elicits different diagnostic results. While the terminal goal is to develop a methodology
that is applicable to physiological sounds (highly variable sounds), by testing several
different levels of non-stationarity the feasibility of such can be more clearly identified.
Table 2.1.2 provides a summary of the testing conditions for sounds acquired at the
blockage surface. Sounds acquired at the VAD are collected on a much less intensive
basis, as the goal of which was limited to determining the feasibility of using sounds
acquired from that location and so a similar table is not provided.

Figure 2-13: In vitro simulator pressure curves with VAD integrated (HM2 at 9200
RPM) at a heart rate of 57 BPM.
49

Figure 2-14: State distribution of the variable BPM experimental data sets parsed by
condition.
The constant heart rate sets (referenced as constant BPM states) are partitioned
into two equal sized groupings of unfaulted and faulted test iterations. Of each group,
100 iterations are used only for classifier training (Chapter 4), while the remaining
30 are reserved solely for classifier testing. Both training and testing iterations are
modulated over the HMAPR. The training sets approximately span the HMAPR,
with no specific gridding, while the testing sets are randomized across the region.
The partitioning of data as such ensures independence in eventual model testing,

Table 2.1: In vitro test conditions.
Heart Rate Pressure State Test Points Test Points Test Points
ID
[BPM]
Region
(Total)
(Healthy)
(Faulted)
1
47
HMAPR
260
130
130
2
57
HMAPR
260
130
130
3
67
HMAPR
260
130
130
4
78
HMAPR
260
130
130
5
Variable
HMAPR
60
30
30
50

Table 2.2: Quadrantized breakdown of HMAPR in vitro training and testing state
locations categorized by MAP Range.
Heart Rate Systolic Pressure
[BPM]
Range [mmHg]
>130 - 111
>130 - 111
47
110 - <90
110 - <90
>130 - 111
>130 - 111
57
110 - <90
110 - <90
>130 - 111
>130 - 111
67
110 - <90
110 - <90
>130 - 111
>130 - 111
78
110 - <90
110 - <90
>130 - 111
>130 - 111
Variable
110 - <90
110 - <90

Diastolic Pressure
Range [mmHg]
>80 - 71
70 - <60
>80 - 71
70 - <60
>80 - 71
70 - <61
>80 - 71
70 - <61
>80 - 71
70 - <60
>80 - 71
70 - <60
>80 - 71
70 - <60
>80 - 71
70 - <60
>80 - 71
70 - <60
>80 - 71
70 - <60

Training Data
Set Points
40
70
29
61
41
45
49
65
45
57
39
59
44
51
49
56
-

Test Data
Set Points
18
17
10
15
18
23
7
12
14
20
9
17
12
25
7
16
15
18
10
17

in instances were a classifier trained at a specific BPM state must be validated at
the same state. Additionally, due to the randomness of the partitioned testing set,
states are not constrained by any means, other than approximately falling within the
HMAPR. Testing points may lie well outside of the space defined by the training
points, and so the randomized sets test for model predictive power and observable
signal variation. An example of the randomized scheme used is given in Figure 2-14 in
which the distribution of states in the variable BPM space is shown. The BPM state
and pressure state (normalized to systolic pressure) are defined for the variable set as
the average values of BPM and pressure over the acquired 15 second interval. Additionally training/testing space mappings are provided in Chapter 4 when discussing
results, however the an immediate general breakdown of state locations relative to
the HMAPR is given by Table 2.1.2.
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2.2

In-Vivo Generation and Acquisition

LVAD patient data collection is performed by Karl Schwarz M.D. of University of
Rochester Medical Center (URMC) using a 3M Litmann digital stethoscope. Both
the patients heart sounds and EKG were collected, and compiled using an NI USB
6212 module. The acoustic signals were sampled at 20 kHz in wideband (no applied
filter) for various auscultation locations and VAD models (Table 2.3). Data collection
is performed externally and so there was no direct control over the consistency of the
data sets, which is most apparent as it relates to the stethoscope positioning (’x’
denotes valid data set). Stethoscope positioning (Figure 2-12) is as follows,
1. Tricuspid: Left 5th intercoastal space
2. Pulmonic: Left 2nd intercoastal space
3. Mitral: Left 5th intercoastal space in the mid clavicular line)
4. Aortic: Right 2nd intercoastal space
5. AAL: Anterior axillary line
6. Subcostal: Area of the subcostal angle
Acoustics are acquired from 18 patients, spanning four different LVAD models:
HeartMate 2 (HM2), HeartMate 3 (HM3), HeartWare (HW), and HVAD. Due to
cycle-to-cycle variation the time domain representation of the heart sounds do not
lead to any intuitive hypothesis. The frequency spectrum however is more telling, as
one can discern trends based on the general distribution of the signal components.
The fast Fourier transform is applied to each patient’s heart sounds resulting in
the signal’s respective frequency spectrum. Across all patients the main frequency
band ranges from 0-50 hz (Figures 2-15 - 2-17). This band contains signal components
specifically relating to native heart sounds and blood flow resulting from the LVAD.
Each LVAD model is run at a frequency either outside of the main frequency band,
or at the extrema of, and so identifying the device frequency component is obvious.
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Figure 2-15: Frequency spectrum of HeartMate 2 (9400 RPM) heart sounds acquired
at the 4 valvular auscultation sites
Additional spectrum components are harmonic factors of the device primary frequency
(PF) as they occur at integer multiples of the PF. The HM2 manifests only a first
harmonic (Figure 2-15) at roughly 350 hz, which is most visible when probed at the
mitral auscultation site, where harmonic propagation appears to be strongest.
While component magnitude may not be greatest at the mitral site, harmonic
propagation (in terms of visible order) is greatest there, while minimal propagation
occurs at the pulmonic site. Both the HW and HVAD (Figures 2-17,2-18) exhibit
high order harmonics around 350 hz due to their comparatively low operating speeds
(2650 and 2800 RPM respectively), while both only exhibit a third harmonic at the
pulmonic site. The HM3 follows a similar trend.
Component magnitude does not appear to follow a consistent trend. The most
obvious reason for such would be patient physicality. Patients with different body
compositions attenuate signals at different rates and so one would not expect there
to be a consistent trend across a multi-patient sample population. What is promising
is that the site of auscultation probing does not appear to affect the shape of the
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spectrum significantly. While magnitudes change depending on the site, the main
frequency band remains consistent, and any additional signal components outside of
this band can be identified as a harmonic of the PF. This similarly appears to be
consistent across the four device models, even those where the PF is at the edge of
the mainband band.
The provided in vivo data is used solely for comparison against the in vitro data,
so that the fidelity of the generated signals can be quantified. Patient information
is tabulated in Table 2.3, however it is not used extensively in this work aside from
comparisons to the in vitro acoustics.

2.3

Data Comparison

It is shown in Figures 2-15-2-18 that the most physiologically significant frequency
bands are 0-50 hz and the PF of the VAD, which may overlap with the previous band
for specific device models and speeds. Given a perfect phantom the same frequency

Figure 2-16: Frequency spectrum of HeartMate 3 (5400 RPM) heart sounds acquired
at the 4 valvular auscultation sites
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Figure 2-17: Frequency spectrum of HeartWare (2650 RPM) heart sounds acquired
at the 4 valvular auscultation sites

Figure 2-18: Frequency spectrum of HVAD (2800 RPM) heart sounds acquired at the
4 valvular auscultation sites
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Table 2.3: In vivo trial patient summary.

VAD
Stethoscope Location
Patient Model Speed (RPM) Aortic Mitral Pulmonic Subcostal Tricuspid AAL
1
HM2
9400
x
x
x
x
x
2
HVAD
2800
x
x
x
x
x
3
HM3
5400
x
x
x
x
x
x
4
HM3
4800
x
x
x
5
HM2
9000
x
x
x
x
x
6
HM2
9000
x
x
x
x
x
7
HM2
13000
x
x
x
x
8
HM3
5500
x
x
x
x
x
9
HM3
5800
x
x
x
x
x
10
HM2
9600
x
x
x
x
11
HM2
10400
x
x
x
x
x
x
4900
x
x
12
HM3
4900
x
x
x
x
x
13
HM3
6100
x
x
x
14
HM2
8600
x
x
x
x
x
15
HW
2650
x
x
x
x
x
16
HM3
5600
x
x
x
x
x
9200
x
x
9600
x
x
17
HM2
10000
x
x
x
x
10400
x
x
10800
x
x
18
HM2
9800
x
x
x
x
x

content would manifest in the acoustics of the simulator, with no restrictions on
component magnitude as the content can be normalized accordingly. No additional
information is given regarding patient blood pressure, demographics, etc. and so this
is the limit of comparison.
The frequency content of the generated in vitro acoustics (Figures 2-19 & 2-20)
consists of the same general two bands, the PF band, and the lower frequency sound
band, termed the mainband. Physiologically, the mainband is resultant from thoracic
and pulmonic sound, along with the process acoustics. The simulator however does
not account for either extraneous thoracic or pulmonic sounds thus all content below
the PF is characteristic of the process (induced flow). The generated mainband
matches the shape of the related band in the patient spectrums (Figure 2-15-2-18),
however the content is located at a higher frequency band, 50-150 hz, with greater
dispersion at the trailing frequencies. Frequency content below roughly 20 hz does
56

Figure 2-19: Frequency spectrum of HM2 (9200 RPM) heart sounds acquired at the
occlusion surface of the simulator unfaulted(left) and faulted(right) consistent state.
State defined as 120/74 at 57 BPM (top) and 120/74 at 78 BPM (bottom).
not exist as the maximum bandwidth of the stethoscope is 20-2000 hz, and so content
at this point is attenuated by the device filter. Peak content is centralized about 110
hz, and so the loss of low frequencies is not expected to be inherently problematic
in discerning condition indicating components however this cannot be definitively
stated. Additionally, high frequency content propagates slightly more so than as was
seen in patients, however this content is not restricted by the bandwidth of the filter.
Within the in vitro mainband two distinct peaks can be identified, which is unlike
the singular peak mainband identified in the in vivo acoustics. These two peaks are
located at approximately 70 hz (noted as PF-A), and at 115 hz (noted as PF-B),
however their exact locations and shape depend on the state. As can be seen in comparing the spectrums of same pressure states, the peaks do not manifest consistently
relative to neither state nor health condition (unfaulted or fault). The inconsistent
fault characteristics can be seen when comparing the states of Figure 2-19 to those
of Figure 2-20, namely in the alteration to the mainband dual peaks.
When the 120/74 mmHg state data is faulted, the simulated 57 beats per minute
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Figure 2-20: Frequency spectrum of HM2 (9200 RPM) heart sounds acquired at the
occlusion surface of the simulator unfaulted(left) and faulted(right) consistent state.
State defined as 106/62 at 57 BPM (top) and 106/62 at 78 BPM (bottom).
(BPM) signal is characterized by decreased magnitudes, with a relatively more decreased PF-B than PF-A. When the heart rate is increased to 78 BPM, the exact
opposite occurs. The PF-B peak sharply increases in magnitude while the PF-A
peak is attenuated. Concerning only the pressure state of 120/74 mmHg this inconsistency would allude to a dependence on state. In order to verify this, a pressure
state of 102/62 mmHg is analyzed, ultimately finding a different trend. Just as the
PF-B of the 120/74 mmHg, 78 BPM state signal had amplified when faulted, so too
does the PF-B of the 106/62 mmHg 57 and 78 BPM states, however in this scenario
so does the PF-A, contrary to what was previously seen. In a similar trend, based
on the findings of Figure 2-19 one would assume both PF-A and PF-B peaks of the
faulted 106/62 57 BPM state to attenuate however both arguably amplify. These
inconsistencies between states indicate a strong dependence on state which is most
likely nonlinear across the HMAPR. This is problematic for diagnostic purposes as
this may mean that diagnostic ability is directly related to the variability that can be
identified, i.e. identifying the inconsistencies, developing peace-wise models, etc.
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Figure 2-21: Time history of HM2 (9200 RPM) heart sounds acquired at the occlusion
surface of the simulator unfaulted(left) and faulted(right) consistent state. State
defined as 120/74 at 57 BPM (top) and 120/74 at 78 BPM (bottom). Both signals
sets are sync’d to the same EKG reference for consistent reference, i.e. 57 BPM sets
are aligned to each other, and 78 BPM data sets are aligned to each other.
Definitive variation and nonlinearity are identified in the frequency spectrum of
the generated acoustics, however the origin of such can be better visualized in the
time domain. When examining the respective time series representations of the signal spectrums shown in Figures 2-19 and 2-20 uniquely occurring components (the
S1 and S2) can be identified. These sounds differ in both magnitude/shape and time
of occurrence. The changes in signal shape can be determined based solely on the respective comparisons shown in Figures 2-21 and 2-22 however sound event occurrence
is not aggressively clear without examining a normalized time space.
When examining the constant heart rate acoustics (for consistent comparison), a
defining characteristic is found. The sound produced by the system does not strictly
depend on the heart rate (BPM state) modulated by the function generator, but
rather is affected by the MAP state as well (Figure 2-23). As the MAP decreases
(i.e. pressure becomes increasingly constant - LVAD dominant system) the S1 and S2
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Figure 2-22: Time history of HM2 (9200 RPM) heart sounds acquired at the occlusion
surface of the simulator unfaulted(left) and faulted(right) consistent state. State
defined as 106/62 at 57 BPM (top) and 106/62 at 78 BPM (bottom). Both signals
sets are sync’d to the same EKG reference for consistent reference, i.e. 57 BPM sets
are aligned to each other, and 78 BPM data sets are aligned to each other.
shift inwards, becoming more closely timed to each other. This is a very particular
and problematic occurrence. The non-stationarity of the signal has been decreased
somewhat because of the constant heart rate modulation, however there remains a
dependence on state. Going forward a constant event frame is desired for examining
specific signal components, however given this system characteristic determining the
exact time of sound occurrences is difficult to achieve. More will be discussed about
this in Chapter 3.
The variations in timing caused by the pressure state is the most likely explanation for the inter-state inconsistencies seen previously in the in vitro frequency
spectrums. The dependence itself is theorized to be the result of how phase and state
are modulated. It was previously noted that due to the constraints of the function
generator, the phase trigger is set to an arbitrary 50/50 timing split, while the exact
rate at which each phase occurs is dependent on the pressure differentials. Because
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Figure 2-23: S1 and S2 in vitro sound event occurrences varying by state. Both
acoustic signals are sync’d to the same EKG reference (bottom graph). Heart rate
of both acoustic signals is 57 BPM. Red boxes indicate S2 sounds, while black boxes
indicate S1 sounds.
of this dependence each phase occurs at varying rates across the HMAPR. It is also
noted that heart sounds (including in vitro signals) are directly resultant from events
such as valvular action and flow perturbations. Thus as the state affects the timing
of events of the in vitro system, the resultant timing of components such as the S1
and S2 also change.
The HMAPR of the in vitro system is characterized by state and condition nonlinearities that make potential diagnostics difficult over the generalized region. Given
the nonlinear timing trend, manual determinations of condition indicating components cannot be made with only time series or frequency spectrum definitions of the
acoustic signal. Additionally, there appears to be innate signal set variation (variation between adjacent cycles) between acoustics at consistent states requiring a robust
processing algorithm that can mitigate variation, and identify condition from state
dependent effects.
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Chapter 3
Digital Signal Processing and Feature
Generation
In general terms, physiological heart sounds are significantly more non-stationary than
the generated in vitro sounds from the heart simulator. The in vitro sounds are not
characterized by any type of cyclical drift, or innate variable rate (can be modulated
as such however), nor are they affected by adjacent tissues, organs, and organ system
processes. While the timing of events does vary with state, this characteristic is a
nonlinearity, not necessarily a non-stationarity.
For this purpose the constant heart rate in vitro acoustics may be considered a
stationary signal, however this is counterintuitive for applications regarding physiological heart sound analysis and the variable heart rate in vitro sounds. There is
a similar issue concerning both signals, in which the intra-cycle variations are not
explicitly indicative of the underlying signal itself, further complicating the analysis,
especially concerning fault scenarios. There are instances when healthy intra-cycle
variations may appear as abnormalities, indicating a false positive diagnostic. There
are also instances where the state dependence would indicate the same incorrect diagnostic result. Eliminating this potential, along with developing a consistent frame
for examining significant signal health components are the objectives of this chapter.
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3.1

Digital Preprocessing

A stationary signal is a signal whose statistical properties do not change over time
for all degrees (expectations, variances, etc.). Absolute stationarity is an aggressive
term, and so for purposes of this work, second order stationarity will be equated to
the general term, stationary. Second order stationarity is the statistical property of
having having constant mean and variance over an interval t ε [t0 ,τ] where τ is the
translation from an arbitrary origin, t0 . Neither the mean nor variance depend on t,
and the autocovariance between states (Xt ,Xt+τ ) depend only on the translation, τ.
Conversely, non-stationary processes are defined as those stochastic processes
which cannot be defined by only τ. As the process’s statistical properties evolve
over time propagation, the interval time, t, is also required to fully define the process statistical states. This is a very significant process characteristic specifically for
signal transformations. Stationary signals require only the translation parameter to
be statistically fully defined, and thus can be defined by n parameters, where n is
the degree of the signal. Non-stationary signals however, require both the translation
parameter along with the specific instance, t, requiring 2n parameters for definition.
This quadratic transformation characteristic will become crucial when determining
spectral properties of the signal.
As to why heart sounds are non-stationary, it is quite obvious. Given two scenarios, S3/S4 occurrence and variable interval period, it becomes apparent to different
degrees. If both the mean and variance of a cardiac cycle are defined for solely the
S1 and S2, then the occurrence of additional sounds (S3, S4, etc.) alters the process
statistical states for the given interval. Given a variable interval rate, the signal statistical properties may remain constant, or near constant, however full definition of the
signal requires quadratic parameters due to the variable interval t0 . As the in vitro
simulator is digitally regulated, neither of these statements hold true for constant
modulated frequency, however as the generated signal is an approximation of the
non-stationary signal, it is processed under the assumption that it is non-stationary.
Assuming a non-stationary heart sound, the first objective is to develop a con64

sistent objective signal to further analyze. The obvious first option is to normalize
the time-series to a [0 1] scale, creating a consistent intra-cycle time scale. Doing so
reduces the variation of the signals as a whole (neglecting storage of the normalization parameter) however does not alter statistical property variation, nor the signal
stationarity properties - both of which are problematic moving forward.
Instead, a new objective signal is generated through ensemble averaging. Ensemble averaging (EA) is the process of creating a set of cyclical data sets (the set
is called the ensemble) and then taking the point-by-point average of the ensemble
to generate a new signal (Figure 3-1). Ensemble averaging reduces signal variation
in the similar way that a moving average does so, reducing, if not eliminating, the
need for filtering (in this instance, eliminating). The resulting statistical properties of
the averaged signal are also unique, in that they are indicative of the most predominant and common properties of the ensemble, thus "filtering" out cycle variation
that is not representative of the underlying signal (such as cycles with additional
sounds/elements/occurrences). Ensemble averaging innately handles process nonstationarity, however leaves the issue of ensemble period variation and identification
of the cycles from the whole acoustic signal. The following work considers only in

Figure 3-1: Ensemble averaging general theory/methodology.
65

vivo signals in developing the algorithm as the produced in vitro acoustics are simpler
and can be processed with the same techniques.
In determining the ensemble, the individual cycles of the objective signal must
first be parsed using an identification routine. The two trialed methods are:
1. Sound Extrema Parsing: Parse individual cycles based on the local maximum
amplitude of the acoustic signal.
2. EKG Extrema Parsing: Parse individual cycles based on the local maximum
amplitude of the relating EKG signal.
Sound extrema parsing involves identifying acoustic signal maxima and accordingly parsing the signal by them. In a non-LVAD patient the maximum signal component occurs during the S1 beat and can be regularly timed (to some degree) and
observed (less than so when unhealthy - Figure 1-2), however as aforementioned in
Chapter 2, the time domain representation of an LVAD patient’s heart sounds are
characterized by significant variation and state dependence reducing feasible application of the signal. EKG extrema parsing is the process by which the peaks of the
EKG signal are identified and subsequently used to parse the acoustic signal. Since
the EKG is a cleaner, and higher fidelity signal, this assumedly results in a more
accurate parse, however requires the EKG signal to be collected, and synchronized
with the acquired sound. This method is specifically examined do to the work performed with the URMC research group. In which a stethoscope is being developed
with integrated EKG leads, enabling EKG extrema parsing.
When using sound extrema parsing (Figure 3-2) the related EKG references (not
peaks as a peak in one signal does not necessitate a peak in the other) do not consistently align at the same EKG wave component. In the dual sense, using EKG extrema
parsing (Figure 3-3) yields a very consistent set of EKG peaks (at the R wave peak)
with no discernible pattern in the acoustic signal, implying that the non-stationarity
of the acoustic process is quite significant. Statistically, parsing by the EKG consistently results in both a lower cycle period deviation (Figure 3.1) and increased
identifiable cycle count as compared to parsing by the acoustic signal. As the EKG is
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Figure 3-2: In vivo signal cycle identification using sound extrema parsing. Black
overlay circles indicate locations of detected peaks of acoustic signal. Peak locations
are overlay on EKG to show correlation.
a relatively high fidelity signal, the deviation of the EKG parsing can be attributed to
the patient’s variable heart rate, i.e. over the one minute acquisition window of the in
vivo signal, the patient’s heart rate did not remain constant, creating a quantifiable
minimal deviation in cycle period.
Even though signal variable rate is identified by each parsing algorithm, the after
effects manifest during the point-by-point averaging of each ensemble due to nonalignment (error resulting from non-equal length signal averaging). As discussed,
there is a minimum quantifiable deviation of each ensemble which is be attributed
to signal variable rate. Even if perfectly parsed, this deviation will cause the cycles
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Figure 3-3: In vivo signal cycle identification using EKG extrema parsing. Black
overlay circles indicate locations of detected peaks of EKG signal. Peak locations are
overlay on acoustic signal to show correlation.

of each ensemble to become misaligned where the severity of the misalignment is
proportional to the distance from the sync point (maximum sound peak or maximum
EKG peak). Assumedly then, signals with the greatest ensemble deviation will yield
the most misalignment resulting in the the terminal average not necessarily being
representative of the underlying signal. Given an inconsistent sync point such as that
produced by sound extrema parsing, the misalignment error will propagate much more
quickly than that resulting from EKG extrema parsing. For this reason, the EKG
signal is used going forward as the universal syncing signal for parsing the ensemble
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Table 3.1: Cycle parsing statistics for both sound extrema and EKG extrema parsing
algorithms.
Auscultation Parsing
Cycles
Cycle Period Cycle Period
Location
Method Identified
Mean (s)
STD (s)
Aortic
Sound
62
.9597
.2721
Aortic
EKG
74
.7952
.0154
Mitral
Sound
71
.8313
.1668
Mitral
EKG
75
.7864
.0217
Pulmonic
Sound
72
.8259
.1885
Pulmonic
EKG
78
.7623
.0087
Tricuspid
Sound
73
.8161
.1572
Tricuspid
EKG
77
.7751
.0179
for both the in vivo and in vitro sounds.
With the acoustic cycles identified by their respective EKG peaks the ensemble
(set of cycles) is now averaged to reduce variation and noise. Four routines are
implemented to study the effects of the misalignment in averaging and potential
remediation actions for such,
1. Unscaled point-by-point averaging (UA).
2. Unscaled point-by-point averaging with acceptable deviation bound (BUA).
3. Linearly scaled point-by-point averaging (SA).
4. Linearly scaled point-by-point averaging with outlier removal (BSA).
Unscaled averaging is the nominal routine, where the ensemble misalignments are
not corrected for - ensembles are aligned and averaged regardless of signal length.
During BUA and BSA the ensembles are reduced according to their deviation from
the average cycle period prior to averaging. Based on a bound control parameter, all
the cycles of the ensemble which lie outside the deviation boundary are omitted from
averaging as it is assumed that they are either not indicative of the underlying signal
or would result in significant misalignment error if included. This process reduces the
overall size of the ensemble, the magnitude of which inversely scales with the size of the
boundary, however assumedly results in an ensemble with reduced misalignment error.
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The final technique, linear scaling, involves taking each cycle, and through a process of
scaling and resampling, maps each to the time-series space of the ensemble’s average
period. This allows for complete point-by-point alignment without reduction of the
ensemble. While beneficial for the above reasons, the validity of scaling [potentially]
significantly different cycles to a consistent basis is unclear, which is the reason for the
fourth remediation routine, BSA. During BSA the ensemble is first reduced as with
BUA, however the remaining ensemble is then scaled and averaged. Given a small
deviation, it can be assumed that cycles within the boundary are approximately the
same signal, and so error propagation inherently arising from scaling is minimized, if
error is in fact an algorithmic product. When using BUA the control parameter is
required to be adequately tight to reduce peak misalignment thus effectively reducing
ensemble size. BSA on the other hand does not remove ensembles for the purpose of
alignment correction, and so the control parameter used in re-parsing the ensemble
is used more so as an outlier removal parameter.
In Figure 3-4 the ensemble misalignment resulting from UA can clearly be seen at
the second R wave of the EKG. Whereas the first peaks of the ensemble align well,
due to it serving as the sync point, the misalignment severity increases away from
this point, creating the peak range seen at the second R wave of the EKG. This, to
a lesser degree, can be seen by the related acoustic average. About the first R wave
peak, the acoustic signal is characterized by increased oscillation, which decreases at
the T wave of the EKG. This however is not the case about the second peak as the
local acoustic signal here is more or less indiscernible from the preceding T wave. The
second R wave peak interval itself is not important as it is just an appended cycle
portion added for comparison, however the visible misalignment propagation that it
indicates is an issue. It is assumed that misalignment is prevalent, to a lesser degree,
during the previous T wave interval as error must propagate along the time scale. Any
indicator of health contained within this interval would then be corrupted posing a
problem in future classification. This is a commonality among all auscultation sites.
By reducing down the ensemble, the BUA routine is able to minimize the alignment variation seen at the second R wave peak location (Figure 3-5). There is still
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Figure 3-4: UA ensemble averaging of in vivo heart sounds from the aortic auscultation site. Black overlay is the averaged signal. RMSE between peak regions is
2.26e-5.

a finite variation to the ensemble, but it has been significantly reduced from what it
was. In order to do so, a 1% variation bound is placed on the ensemble - any cycle
whose period differs from the mean period by more than 1% is omitted from the
ensemble composition. While it produces an improved average signal, it also reduces
the ensemble from 74 cycles to 26, a reduction of two-thirds. Such a reduction is
not practical as it requires a three fold increase in raw data collection. Additionally,
there is nothing inherently wrong with the committed data sets (assumedly) and so
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the omittance of such is not necessarily justified.
The misalignment resulting from UA and BUA is a direct result of patient heart
rate variability. The relative error of the alignment is thus directly related to heart
rate variation. Extrapolating this to the in vitro data, given the constant heart rate
modulated data sets, UA results in a near perfect point-by-point ensemble average
(+- a sample due to decimation or rounding) thus not requiring a more intensive
algorithm. This however is not true for the variable frequency tests, nor the in vivo

Figure 3-5: BUA ensemble averaging (>1% deviation from mean period reduction) of
in vivo heart sounds from the aortic auscultation site. Black overlay is the averaged
signal. RMSE between peak regions is 2.72e-6.
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signals.

3.1.1

Polyphase Decomposition Scaling

As shown in Figure 3-5 BUA reduces the ensemble misalignment at the cost of significant data quantity loss (66%), the severity to which scales with the degree of
the permitted misalignment. This is both extremely impractical for real-time application and allows for a permissible misalignment which propagates error along the
time scale. The misalignment error propagation is a result of the process frequency
non-stationarity rather than that which manifests in various signal components. The
magnitude of the latter of the mentioned non-stationarities is reduced through ensemble averaging, while the frequency based non-stationarity is mitigated through
control of the ensemble size in BUA.
Both SA and BSA apply a scaling transformation to the ensemble to reduce misalignment propagation along the time scale of the ensemble without inherent data
reduction. The transform essentially dilates or constricts the objective ensemble cycle given its deviation from the average time scale of the ensemble. This results in
a transformed signal, with a process frequency exactly matching the average of the
ensemble process. This, however, does pose two issues,
1. The transformation must be compatible with point-by-point averaging.
2. The transformation must be applied in such a way to preserve as much frequency
content as possible, without generation of erroneous content.
The transformation must first off be compatible with how the ensembles are averaged, point-by-point. To achieve this with no misalignment propagation, each transformed signal must be of the same size and discretization assuming the same sampling
rate. This is problematic as scaling any discrete set results in a new discretization
of the set, that is assumedly inconsistent with the related ensemble. Assuming this
condition will be met, the transformed signal must still be indicative of the original
signal to be of potential use. Clearly in terms of reducing non-stationarity charac73

teristics this is beneficial, however scaling transformations do not [exactly] preserve
stationarity components.
The PF and harmonics of the VAD variably manifest in the frequency spectrum of
patients (Figures 2-15-2-18) and the simulator (Figures 2-19-2-20). Considering that
90% of VADs are continuous flow devices with speed control, the frequency content
related to the devices are considered stationary components that do not require scaling. Dilation of the cycle will result in all frequency content of the cycle shifting down
(decreasing) while constriction results in an upwards shift (increasing) in content. A
scaling transformation across the entire ensemble then shifts each cycle’s device frequency content to an assumedly different frequency band. While this is not entirely
problematic, once the ensemble is averaged, due to the inconsistent bands, the PF
and harmonic bands are either warped or eliminated. Potential condition indicators
within this band are then also lost, however as the device process is stationary and
controlled, one would not expect an indicator to manifest here and is therefore inconsequential for identification purposes. To ensure that the inconsistencies resulting
from this do not affect classifications they are later further dealt with in Chapter 3.3.
In order to compensate for the re-discretization of the signal caused by scaling,
the signal is first resampled in such a way that post-scaling aligns the ensemble to the
desired length and original discretization. Re-discretization is performed by upsampling, smoothing, and subsequently low pass filtering and downsampling, however
this procedure is non-optimal for this work. As is shown in Figure 3.1 parsing by
the EKG signal significantly decreases cycle period deviation from the mean of the
ensemble. This, while obviously beneficial for parsing, essentially ensures that resampling must be done with relatively high factors. To be computationally optimal
both the upsampling and downsampling must be performed with factors of the least
common multiple (LCM) between the mean cycle and individual cycle lengths as
period scaling is the desired transformation. By achieving small period deviations,
non-integer ratios between lengths result. Conversion from these ratios to rational
approximations, so that resampling can be performed, results in large LCMs, meaning
resampling must be performed at very high computational costs due to large filter
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coefficient vectors. Additionally, in order to resample, by means of the method prescribed above, requires filtering after upsampling and prior to downsampling. The
design of both filters depend on the resampling factors resulting in two fold large filter
applications, an obvious inefficiency.
Algorithmic efficiency is increased by instead performing polyphase decomposition
(PD) filtering to achieve the desired discretizations of the ensemble. Given that the
resampling ratio (quotient of upsample factor and downsample factor) is rational,
a singular FIR filter (polyphase resampler filter - PRF) can be designed for both
upsample smoothing and downsample anti-aliasing. If resampling cost is defined as
the product of the resampling factors, PD reduces said cost by the maximum factor,
making resampling much more efficient than two step resampling.
In PD, upsampling is performed by re-discretizing based on the upsampling rate
and inserting zeros at the added points. Downsampling is performed by removing
points based the downsampling rate. The PRF both smooths the added zeros, while
low pass filtering at the desired Nyquist frequency for anti-aliasing. The filter properties are achieved through the design of the windowing function, a kaiser window
[16].
The kaiser window, a modified zero-ith order Bessel function is defined as,
⎧
⎨𝐼 [𝛽(1 − [(𝑛 − 𝛼])/𝛼)]2 )1/2 ], 0 ≤ 𝑛 ≤ 𝑀
0
𝑤[𝑛] =
⎩
0,
𝑒𝑙𝑠𝑒

(3.1)

where 𝐼0 [*] is the Bessel function, 𝑀 is the filter order, 𝛼 = 𝑀/2, 𝛽 is a window
shape parameter, and 𝑛 is the sample. Design of the window depends only the filter
order, 𝑀 , and the shaping parameter, 𝛽, but the choice of each depends on the filter
characteristics, which are normalized to the sampling rate (frequency units are 𝜋
rad/sample).
Given a rational resampling rate, 𝑅 = 𝑝/𝑞, the following equations define the
transition band of the filter (Figure 3-6),
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Figure 3-6: FIR filter frequency response [26].

𝑃 𝑎𝑠𝑠𝑏𝑎𝑛𝑑 𝐹 𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 [𝜋 𝑟𝑎𝑑/𝑛] : 𝜔𝑝

(3.2)

𝑆𝑡𝑜𝑝𝑏𝑎𝑛𝑑 𝐹 𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 [𝜋 𝑟𝑎𝑑/𝑛] : 𝜔𝑠

(3.3)

𝑇 𝑟𝑎𝑛𝑠𝑖𝑡𝑖𝑜𝑛 𝐵𝑎𝑛𝑑 (𝑇 𝐵) [𝜋 𝑟𝑎𝑑/𝑛] : ∆𝜔 = 𝜔𝑠 − 𝜔𝑝
𝑇 𝐵 𝐶𝑒𝑛𝑡𝑒𝑟 𝐹 𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 [𝜋 𝑟𝑎𝑑/𝑛] : 𝜔𝑐 =

𝜔𝑠 + 𝜔𝑝
1/2
=
2
𝑚𝑎𝑥(𝑝, 𝑞)

(3.4)
(3.5)

The transition band center of the filter, 𝜔𝑐 , generates the Nyquist frequency of
the resampled signal. In PD, a singular filter is used, requiring 𝜔𝑐 to be set to the
more restrictive Nyquist frequency that would be used regarding separate upsample
and downsample filters. This guarantees that the other Nyquist frequency condition,
being less restrictive, will inherently be satisfied. If resampling to a smaller sampling
rate (𝑝 > 𝑞) then 𝜔𝑐 is most restricted by equating to.5𝑝−1 . Conversely, if resampling
to a larger rate (𝑝 < 𝑞) then 𝜔𝑐 is most restricted by equating to .5𝑞 −1 .
The shape parameter, 𝛽, controls sidelobe attenuation, 𝛿𝑠 and affects mainlobe
width, while the filter order, 𝑀 , affects mainlobe width. The relation between 𝑏𝑒𝑡𝑎
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and 𝛿𝑠 is as follows,

𝑆𝑖𝑑𝑒𝑙𝑜𝑏𝑒 𝐴𝑡𝑡𝑒𝑛𝑢𝑎𝑡𝑖𝑜𝑛 [𝑑𝐵] : 𝐴 = −20𝑙𝑜𝑔10 (𝛿𝑠 )
(3.6)
⎧
⎪
⎪
0.1102(𝐴 − 8.7),
𝐴 > 50
⎪
⎨
𝐵𝑒𝑡𝑎 [−] : 𝛽 = .5842(𝐴 − 21).4 + .07886(𝐴 − 21), 21 ≤ 𝐴 ≤ 50
⎪
⎪
⎪
⎩
0,
𝐴 < 21
(3.7)
Sidelobe attenuation is only affected by 𝛽, i.e. increasing 𝛽 results in increased
attenuation of the sidelobe. Increasing 𝛽 also has the effect of increasing the width of
the mainlobe. As it exhibits both behaviors, the viable range of 𝛽 is quite significant
as 𝑀 can reduce the mainlobe width while still achieving high stopband attenuation.
Given the order of the filter, the mainlobe width and specific transition bands can be
determined (mainlobe indirectly from transition band),

𝐴 − 7.95
2𝜋2.285∆𝜔
𝑀
𝐹 𝑖𝑙𝑡𝑒𝑟 𝑂𝑟𝑑𝑒𝑟 𝑁 𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 [−] : 𝑛 =
𝑚𝑎𝑥(𝑝, 𝑞)
𝐹 𝑖𝑙𝑡𝑒𝑟 𝑂𝑟𝑑𝑒𝑟 [−] : 𝑀 =

𝑊 𝑖𝑛𝑑𝑜𝑤 𝐿𝑒𝑛𝑔𝑡ℎ [𝑠𝑎𝑚𝑝𝑙𝑒𝑠] : 𝐿 = 𝑀 + 1

(3.8)
(3.9)
(3.10)

where n is the order of the downsample anti-aliasing filter. Thus given the window
length and 𝛽 of the window nearly all filter characteristics can be approximated. The
passband ripple, 𝛿𝑝 is a result of both the window type and 𝛽 and so it is not an
exact design parameter, however the ripple width is inversely related to the window
length, i.e. longer window gives shorter ripples. This realization is not significant
unless there is significant frequency content about the passband boundary as ripple
error increases with frequency.
As the design process would suggest, in order to achieve a specific set of filter
characteristics based on a unique 𝑅 requires a unique set of (𝛽, 𝐿). This is impractical
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due to both the magnitude of the cycles to transform (requires a different filter per
- each must be auto-generated) and for the fact that under specific permutations,
achieving specific parameters may require inefficient design parameters (arbitrarily
high order). Instead, knowledge of the ensemble’s frequency content can be leveraged
in order to design a filter that is applicable for all cycles.
The highest frequency content seen in patients and from the in vitro simulator
is roughly 500 hz (Figures 2-15-2-18,2-19-2-20) seen with the HM2, with the most
significant band spanning 0-50 hz irregardless of device and 50-150 hz. Assuming these
bands are indicative of the population, the maximum frequency, 𝜔𝑚𝑎𝑥 can be finitely
defined. This frequency would is then defined as the absolute minimum resampled
Nyquist frequency admissible in order to preserve significant signal content. There
is significant higher frequency content, however the exact preservation of such is
negligible as it is shown that this content is harmonic based which ensemble averaging
innately warps/eliminates. Given an ideal LPF the transition band center (ideal filter
implies: 𝜔𝑐 = 𝜔𝑝 = 𝜔𝑠) can be placed at 𝜔𝑚𝑎𝑥 however the PRF is non-ideal. The
passband of the filter must then be placed, at minimum, at 𝜔𝑚𝑎𝑥 to ensure, assumedly,
non-attenuation of the desired passband (𝜔𝑝−𝑚𝑖𝑛 = 𝜔𝑚𝑎𝑥 ).
Placing 𝜔𝑝 = 𝜔𝑝−𝑚𝑖𝑛 is problematic as the passband ripple increases in amplitude
near 𝜔𝑝 , resulting in warping of the content. An arbitrarily high order filter can in
theory mitigate this, however is computationally inefficient. The practical solution is
obvious, placement of the passband arbitrarily far away from the highest frequency
content will preserve the necessary content while achieving the desired resampled
Nyquist frequency.
How far the Nyquist is placed away depends only on 𝑅 which is inherently beneficial. As explained in Chapter 2, the M3 stethoscope samples at 20 kHz, meaning the
frequency band of 500-10000 hz (referenced as the ’voidband’) carries no significant
content. The resampled Nyquist frequency, the transition band center, is a scaled
version of the original Nyquist, specifically by 𝑅 (3.5), thus to achieve the nominal
resampled Nyquist, the normalized 𝜔𝑐 must be scaled by the upsample factor and
original sampling rate. Thus given an arbitrary void band, the minimum permissible
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𝑅 can be found,

𝑅* = 𝑚𝑖𝑛{𝑅𝑖 (𝑝, 𝑞)} 𝑓 𝑜𝑟 𝑖 = 1, 2, ..., 𝑠𝑖𝑧𝑒(𝑒𝑛𝑠𝑒𝑚𝑏𝑙𝑒)
𝑆𝑢𝑏𝑗𝑒𝑐𝑡 𝑡𝑜 :

(3.11)

𝑝<𝑞

Given p > q, 𝜔𝑐 is placed at the original Nyquist, thus the constraint. Given the
solution, 𝑅* to 3.11 the necessary condition for ensemble resampling is,

𝑅* >

𝑤𝑚𝑎𝑥
𝑓𝑠

(3.12)

The minimum frequency of the voidband, denoted 𝜔𝑚𝑎𝑥 , is the minimum permissible frequency that the transition band center can be placed. Placement of 𝜔𝑐 at
𝜔𝑚𝑎𝑥 however results in attenuation of passband content due to the transition band
so the passband is instead bounded, 𝜔𝑝 ≥ 𝜔𝑚𝑎𝑥 , to ensure no loss of content. Placement of 𝜔𝑝 = 𝜔𝑚𝑎𝑥 constitutes the bandwidth requirement for a minimal order filter.
Given the large void-bandwidth, the passband is significantly smaller than the transition band for the minimal order filter ("Bad filter practice"), and so an additional
constrain is imposed, 𝜔𝑝 > ∆𝜔. With the above constraints,

𝑃 𝑎𝑠𝑠𝑏𝑎𝑛𝑑 𝐹 𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 [𝜋 𝑟𝑎𝑑/𝑛] : 𝜔𝑝 = 𝑎𝜔𝑐

(3.13)

𝑆𝑡𝑜𝑝𝑏𝑎𝑛𝑑 𝐹 𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 [𝜋 𝑟𝑎𝑑/𝑛] : 𝜔𝑠 = 𝑏𝜔𝑐

(3.14)

𝑤ℎ𝑒𝑟𝑒 : 𝜔𝑚𝑎𝑥−𝑛𝑜𝑟𝑚 < 𝑎 < 1,
1 < 𝑏 < 2,

𝑠𝑢𝑐ℎ 𝑡ℎ𝑎𝑡 𝑎 ≥ 2/3 (3.15)

𝑠𝑢𝑐ℎ 𝑡ℎ𝑎𝑡 𝑖𝑡 𝑖𝑠 𝑠𝑦𝑚𝑚𝑒𝑡𝑟𝑖𝑐

(3.16)

𝑤𝑖𝑡ℎ 𝑎 𝑎𝑏𝑜𝑢𝑡 𝜔𝑐
where

𝜔𝑚𝑎𝑥−𝑛𝑜𝑟𝑚 =
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𝜔𝑚𝑎𝑥
𝑓𝑠 𝑝

(3.17)

The filter frequency properties are fully defined by the given equations and constraints. The passband is placed relative to content, the Nyquist is resultant from 𝑅,
and the stopband is arbitrarily symmetric. Given that the passband is placed such
that 𝑎 = 2/3, the modified requirement for minimum order design is now been met.
In the traditional kaiser window design process, window length and 𝛽 are inputs
that define the shape and characteristics of the resulting filter, which are then used
to define the transition bandwidth (3.8). By constraining the problem as in 3.13-3.16
the transition band is know, and if 𝑎 = 2/3 the necessary condition for minimum
order is met. Using (3.8) the minimum required order of the filter is found such that
it achieves the desired stopband attenuation with the designed band parameters.
Analyzing the ensemble of Figures 3-4 and 3-5 the highest significant frequency
content is the harmonic at 150 hz (Figure 2-15, however there is sparse content from
150-500 hz. With the ensemble characterized by 𝑅* = .9725 placement of 𝑤𝑝 must be
at a minimum nominal frequency of 6484 hz to satisfy 𝑎 ≥ 2/3. The attenuation, 𝛿𝑠
was arbitrarily set to .001. The normalized, minimal filter order of the ensemble is 6.
Using SA (Figure 3-7) the error propagation is severely decreased, as is the case with
BUA (Figure 3-5), however without the reduction in ensemble size. Additionally, it
can be inferred from the R wave zooms (Figure 3-5 - 3-7) that SA results in a higher
fidelity average due to the decrease in error propagation, which is confirmed from R
wave RMSE quantification.
In taking the same approach as was done with BUA, the ensemble is likewise
bounded in BSA using deviation from the mean period as criteria. Bounding the
ensemble deviation by one standard deviation results in an ensemble size reduction of
36% with little obvious effect (Figure 3-8). The effect of the reduction is consistent,
the difference between signals (Figure 3-9) oscillates about zero with no trend. The
relative effect of bounding is most apparent between R wave peaks as signal magnitude
is comparatively less in this region, which does indicate an intermittent trend. During
this interval (approximately .3-.7 seconds) whichever way the BSA signal inflects is of
greater magnitude than the related SA signal indicating the signals that were omitted
create a bias towards zero. This could indicate that the omitted data carries some
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sort of intrinsic error or more interestingly could imply that scaled signal fidelity is
related to the magnitude of the scale. This remains an undetermined fact and so for
the practical application of the algorithm SA is strictly used in this work.
Between the SA and BSA there is little discernible difference. Even when comparing the scaled averages to the BUA signal, the difference in error propagation isn’t
as obvious a determination, as a time series. Instead, the frequency content (3-10) of
the signals better characterize the effects of each routine.
The correlation between the BUA, SA, and BSA signals are comparatively high,

Figure 3-7: SA ensemble averaging of in vivo heart sounds from the aortic auscultation
site. Black overlay is the averaged signal. RMSE between peak regions is 4.19e-7.
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with UA being the signal of objectively lesser fidelity. The non-alignment caused
by UA creates a different frequency spectrum shape, as compared to the other spectrums, where prominent components are degraded to a degree. Those most significant
components, being located at 12 hz and 20 hz, are more clearly defined in BUA, SA,
and BSA implying that these components are directly related to the improvement in
ensemble alignment. This theory is supported by the fact that the scaling routines
result in equal magnitude significant components. Being that those two magnitudes

Figure 3-8: BSA ensemble averaging (36% ensemble reduction) of in vivo heart sounds
from the aortic auscultation site. Black overlay is the averaged signal. RMSE between
peak regions is 4.19e-7.
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are globally the greatest it can be assumed that they relate to acoustic components
timed at the R wave peaks, which are previous used to compare error propagation in
the time domain (Figures 3-4-3-8). Outside of those peaks, the trailing band (20-40
hz) is of a slightly different shape comparing between the scaling routines and BUA.
The BUA signal is attenuated slightly more and with less peaking compared to the
scaling algorithms. As theorized, the PF at 155 hz is attenuated by the scalingaveraging combination, however the PF is not significantly present in either the UA
or BUA signals. While scaling does increase stationary component attenuation, averaging appears to be of more significant impact. Finally, there is little difference
between spectrums resulting from SA and BSA, confirming the decision that SA is
to be used until more is known about the impact rejection has on the scaled signal
averages.

Figure 3-9: Comparison of averaged signal resulting from both the SA and BSA
algorithms.
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3.1.2

Ensemble Averaging Nonlinear Spectrum Effects

All four averaging routines (UA, BUA, SA, and BSA) are able to effectively reduce
both the noise and cycle-to-cycle variation, or non-stationarities, of the ensemble.
Temporal misalignment decreases proportional to the degree of which the ensemble
is bounded, or is entirely eliminated when scaling the ensemble to a consistent basis.
Alternatively, the device frequency is seen to severely attenuate as a result of both
averaging and scaling, which poses the question of how the frequency spectrum is
altered as a result ensemble averaging.

Figure 3-10: Comparison of the frequency content of the averaged signals resulting
from UA (top), BUA (middle-top), SA (middle-bottom), BSA (bottom).
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Ensemble averaging can in theory be defined through filter parameters however
such assumes that the signal being averaged is statistically stable, or rather stationary.
If a signal is completely stationary then its quality can be defined in terms of its signalnoise ratio. If then averaging an ensemble of this type of signal, the averaged signal’s
signal-noise ratio can be defined as [25],

(︂

𝑆
𝑁

)︂
=

√

(︂
𝑛

𝑛

𝑆
𝑁

)︂

(3.18)

𝑖

𝑤ℎ𝑒𝑟𝑒 : 𝑆 = 𝑆𝑖𝑔𝑛𝑎𝑙 𝑃 𝑜𝑤𝑒𝑟
𝑁 = 𝑆𝑖𝑔𝑛𝑎𝑙 𝑁 𝑜𝑖𝑠𝑒
𝑛 = 𝑆𝑖𝑧𝑒 𝑜𝑓 𝐸𝑛𝑠𝑒𝑚𝑏𝑙𝑒
The ratio of S to N is defined as the signal-noise ratio (SNR). Given that the signal
is stationary, the SNR of the average scales with the square root of the ensemble size,
and so by increasing the ensemble size the resultant average is increasingly filtered.
This formulation however requires that the noise is zero mean and constant variance,
i.e. the signal is statistically invariant. For this work the non-stationarity of the in
vivo acoustics (and in vitro acoustics to a lesser degree) is generalized as a noise term.
Due to this, the signal is no longer statistically invariant and so the SNR must be left
in its generalized form,
(︂

𝑆
𝑁

)︂
=
𝑛

∑︀𝑛
𝑆𝑖
√︀∑︀𝑖=1
𝑛
2
𝑖=1 𝜎𝑖

(3.19)

From 3.19 it becomes apparent that the performance of the average as a filter
depends on the individual cycles of the ensemble and their statistical characteristics.
Filter performance is no longer improved by arbitrarily increasing the ensemble size.
Of more consequence to this work is if the the noise is not zero mean, constant
variance over an individual cycle. Given the generalization that non-stationarities
are considered signal noise, the resulting noise is then skewed to reflect the properties
of the variation. This may be resulting from an inconsistent sound, or may result
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from misalignment. Additionally, due to the inherent nonlinear phase timing of the
system, it is theorized that noise is specifically dependent on phase for the in vitro
acoustics.
The in vitro acoustics are the optimal test of ensemble average filter performance
and/or characteristics. The constant BPM sets are not characterized by misalignment, nor is the system characterized by inconsistent events (S3,S4) as the in vivo
acoustics may be. This being the case, if the system is not characterized by phase
specific non-stationarities, then the performance of the algorithm is expected to follow the definition of 3.18. In examining the spectra of the in vitro UA signal (3-11),
this roughly appears to be the case with some exception. The first noticeable characteristic of the spectrums is that they all share the same shape near the mainband.
Additionally, as the ensemble size increases, noise, specifically within 200-500 hz,
decreases with increasing ensemble size which is expected. A more problematic occurrence is the attenuation of the LVAD PF and related harmonic signals. As the
ensemble is increased to a size of two, the PF immediately attenuates, and continues
to do so with increasing size. This occurrence may suggest a handful of realizations.
Ensemble averaging may innately filter the ’point’ components as noise, meaning that
any component that manifests consistently at very specific frequency may be attenuated. This is weakly backed-up by harmonic component attenuation, however that
does not occur at a consistent manner to PF attenuation, and by the local spectrum
about the PF. The content about the PF is filtered, however is not disproportionately attenuated, supporting this theory. Outside of the the device frequency content,
the mainband components maintain shape, and roughly converge to the raw signal
(unaveraged) spectrum magnitudes (top left plot of Figure 3-11).
These spectrum characteristics are consistent across the in vitro data. The PF
and related harmonic content is diminished however the mainband content is comparatively unaltered. Additionally, when examining the area under the curve for
the averaged signal spectrums the area does appear to consistently follow a decaying
exponential trend, as in the area asymptotes with increasing ensemble size.
In examining the in vivo signal frequency component averages, not only can the
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Figure 3-11: Frequency content of in vitro signal after varying ensemble size unscaled
averages. Circles in indicate three most significant components of the individual
cycles. BPM state is 78 BPM.

difference between the scaled and unscaled averages be seen, but a clear deviation
from the optimal SNR filter (3.18) can be quantified. While the PF and harmonic
content is similarly attenuated and the mainband magnitudes show asymptotic behavior, the mainband content is somewhat magnified, or at least inconsistently with
respect to the in vitro manifestation of the mainband. While not necessarily a nonlinear filter effect, this does suggest that lower frequency content converges at a slower
rate than higher frequency content. Specifically in this case, in order to approximately achieve the magnitudes of the raw signal spectrum compiled from 16 cycles,
requires an ensemble size of 64 cycles. Unlike the phenomenon seen with the PF and
harmonic content, the entirety of the mainband content appears to consistently magnify/attenuate. Although this is true, the ’area under the curve’ metric as a function
of ensemble size does asymptote as with the higher frequency in vitro signal averages,
indicating some optimal filtering characteristics.
Although showing some linear filter characteristics, ensemble averaging is a non87

Figure 3-12: Frequency content of in vivo signal after varying ensemble size unscaled
and scaled averages. Circles in indicate three most significant components of the
individual cycles.
linear transformation. Asymptotic behavior of the signal spectrum shape implies
that the resulting signal is stable, however the rate at which the routines converge to
relatively invariant ensemble size definitions cannot be analytically quantified. Examining how the signal spectrums change as a result of algorithm and size shows that
the unscaled routines exhibit more linear behavior, in the impact on the resulting
averaged signal. The unscaled in vivo spectrums (Figure 3-13) achieve rough asymptotic behavior at an ensemble size of 10, whereas the scaled spectrums (Figure 3-14)
require a larger size, approximately 15. Similarly, at low ensemble sizes (< 5) the
scaled averages are characterized by high variation in shape exceeding that seen with
the unscaled signals. These differences are believed to be resultant from resampling.
Upsampling and downsampling are time-varying operations (do not commute) and so
this characteristic of the operations further increases the generalized degree of nonlinearity of the averaged signal, which is most prominent at low ensemble sizes. Without
prior knowledge of how the signal statistical parameters (both noise-wise and non)
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change with respect to time, the full effects of ensemble averaging cannot be quantified. However based on the empirical results, stability of the resulting signal appears
to be guaranteed (assuming the PRF is correctly designed), along with the related
frequency content of the signal asymptotically trending to an ensemble-size invariant
shape. If the feasible ensemble size is restricted (low number of cycles), scaling is not
appropriate as it has the highest chance of spectrum shape distortion at low sizes. If
the ensemble size is not limited then scaling is the optimal algorithm relative to the
preservation of timing and content.

Figure 3-13: Stability metrics for unscaled average of in vivo signal spectrums of
Figure 3-12.
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Figure 3-14: Stability metrics for scaled average of in vivo signal spectrums of Figure
3-12.

3.2

Time-Frequency Spectra Composition

From the time series definition of the SA acoustic and EKG signals, the specific cardiac
cycle intervals can be inferred. Using the EKG as a reference this is elementary,
however the QRS complex peak acoustic is characterized by increased magnitude
oscillations, as seen in healthy heart sounds of non-VAD patients (Figure 1-2). By
analyzing the effects of scaling on the EA signals, select R wave components are able
to be identified in the related frequency domain definitions of said signals, however
in general there is no general visual correlation that can be determined.
Specific events in the cardiac cycle are known to elicit specific resulting sounds.
In the event of occulsion we expect some quantifiable event to indicate that such
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has occurred, which would then manifest as an observable sound. Due to the nonstationarity of the cycle, along with the lack of time resolution in the frequency
domain, or the lack of frequency resolution in the time domain, the identification of
specific events is not possible. Identificaiton of such requires a signal definition with
both time and frequency resolution so that specific signal components can be discerned
from the adjacent space which would otherwise create bias and redundancy. When
considering only two conditions, such a resolute defintion may not be required [28]
however a clearly emanating bias/trend cannot be assumed for every malcondition.
Similarly, compounded issues may manifest uniquely, in which case having both time
and frequency resolution would be helpful in parsing condition.
A common technique historically used for time-frequency definition of signals is
the short time Fourier transform (STFT). As the name would imply, the transform
like the Fourier transform provides frequency information about a signal, however
over a short time interval, by decomposing a signal into a trigonometric basis. Thus
by compiling many iterations of the transform, a resulting time-frequency definition
is determined.

∫︁

∞

𝑆𝑇 𝐹 𝑇 {𝑥(𝑡)} (𝜏, 𝜔) ≡𝑋(𝜏, 𝜔) =

𝑥(𝑡)𝑤(𝑡 − 𝜏 )𝑒−𝑗𝜔𝑡 𝑑𝑡

(3.20)

−∞

𝑤ℎ𝑒𝑟𝑒 : 𝑥(𝑡) = 𝑜𝑟𝑖𝑔𝑖𝑛𝑎𝑙 𝑡𝑖𝑚𝑒 𝑠𝑒𝑟𝑖𝑒𝑠 𝑠𝑖𝑔𝑛𝑎𝑙
𝑡 = 𝑡𝑖𝑚𝑒 𝑣𝑎𝑟𝑖𝑎𝑏𝑙𝑒
𝜔 = 𝑓 𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 𝑣𝑎𝑟𝑖𝑎𝑏𝑙𝑒
𝜏 = 𝑡𝑟𝑎𝑛𝑠𝑙𝑎𝑡𝑖𝑜𝑛 𝑝𝑎𝑟𝑎𝑚𝑒𝑡𝑒𝑟
𝑤 = 𝑤𝑖𝑛𝑑𝑜𝑤𝑓 𝑢𝑛𝑐𝑡𝑖𝑜𝑛

The STFT utilizes a translated windowing function to achieve specific frequency
resolution at a given time instance. The wider the window, the greater the frequency
resolution, at the cost of time resolution. The narrower the window, the greater the
time resolution at the cost of frequency resolution. This trade-off is the result of the
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frequency discretization of the window function. Given a window of 𝑁 length and
sampling rate 𝑓𝑠 , the frequency discretization is defined as 𝑓𝑠 /𝑁 . Thus the only way to
improve frequency resolution is to increase window length, resulting in fewer samples
per unit time. Over specific intervals this trade-off may not be significant, however
when concerning the entirety of a signal results in skew resolution. This is specifically
important to this work as potential indicating components, of wide ranging conditions,
may appear at any region of the spectra. With that being the case it is important to
generate a time-frequency representation with consistent resolution across the space
it defines.
The STFT utilizes a constant length window function to define a fixed frequency
resolution, which was shown to limit time resolution. Given an additional transformation variable, multi-resolution analysis of the signal can be achieved as is done with
the continuous wavelet transform (CWT). The CWT operates on a similar principle
as the STFT, in that it decomposes a signal into a basis set, however the CWT does
so without a window function, 3.21. Instead, the CWT utilizes a modulated scalable
window to achieve multi-resolution across a signal,

𝐶𝑊 𝑇 {𝑥(𝑡)} (𝑎, 𝑏) ≡𝛾(𝑎, 𝑏) =

1
|𝑎|1/2

∞

(︂
)︂
𝑡−𝑏
¯
𝑥(𝑡)𝜓
𝑑𝑡
𝑎
−∞

∫︁

(3.21)

𝑤ℎ𝑒𝑟𝑒 : 𝑥(𝑡) = 𝑜𝑟𝑖𝑔𝑖𝑛𝑎𝑙 𝑡𝑖𝑚𝑒 𝑠𝑒𝑟𝑖𝑒𝑠 𝑠𝑖𝑔𝑛𝑎𝑙
𝑡 = 𝑡𝑖𝑚𝑒 𝑣𝑎𝑟𝑖𝑎𝑏𝑙𝑒
𝑎 = 𝑠𝑐𝑎𝑙𝑖𝑛𝑔 𝑣𝑎𝑟𝑖𝑎𝑏𝑙𝑒
𝑏 = 𝑡𝑟𝑎𝑛𝑠𝑙𝑎𝑡𝑖𝑜𝑛 𝑣𝑎𝑟𝑖𝑎𝑏𝑙𝑒
𝜓¯ = 𝑚𝑜𝑡ℎ𝑒𝑟 𝑤𝑎𝑣𝑒𝑙𝑒𝑡 𝑐𝑜𝑚𝑝𝑙𝑒𝑥 𝑐𝑜𝑛𝑗𝑢𝑔𝑎𝑡𝑒
𝛾(𝑎, 𝑏) = 𝑤𝑎𝑣𝑒𝑙𝑒𝑡 𝑐𝑜𝑒𝑓 𝑓 𝑖𝑐𝑖𝑒𝑛𝑡𝑠
Whereas the window function of the STFT is dependent only on the translation
parameter, the mother wavelet is both translated and scaled, to produce the daughter
wavelets that are convolved with the objective signal. The mother wavelet is not an
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explicit function, there are several potential basis functions for such, however this
then means that the coefficient matrix of the transform is uniquely dependent on the
choice of basis function. To be a valid basis function the mother wavelet must satisfy,

∫︁
𝐴𝑑𝑚𝑖𝑠𝑠𝑖𝑏𝑖𝑙𝑖𝑡𝑦 :

|𝐹 {𝜓(𝑡)}|2
𝑑𝜔 < ∞
|𝜔|

𝑍𝑒𝑟𝑜 𝐹 𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 : |𝜓(𝜔 = 0)|2 = 0
∫︁
𝑇 𝑖𝑚𝑒 𝐷𝑜𝑚𝑎𝑖𝑛 𝑍𝑒𝑟𝑜 𝑀 𝑒𝑎𝑛 :
𝜓(𝑡)𝑑𝑡 = 0
𝑅𝑒𝑔𝑢𝑙𝑎𝑟𝑖𝑡𝑦 * : 𝛾(𝑎, 0) 𝑑𝑒𝑐𝑎𝑦𝑠 𝑎𝑡 𝑎𝑛+2

(3.22)
(3.23)
(3.24)
(3.25)

𝑤ℎ𝑒𝑟𝑒 : 𝐹 {} = 𝐹 𝑜𝑢𝑟𝑖𝑒𝑟 𝑡𝑟𝑎𝑛𝑠𝑓 𝑜𝑟𝑚

Admissibility states that the frequency normalized 𝐿2 norm of the of the basis
Fourier transform is finite. By restricting the basis as such guarantees that the signal
can be reconstructed from the coefficient matrix without loss of information. While
not entirely obvious the zero frequency condition implies that wavelets have a bandpass like spectrum. In order to have finite frequency content the spectrum must inflect
upwards (and subsequently downwards) an arbitrary distance from 𝑜𝑚𝑒𝑔𝑎 = 0. As
the basis is a set of transformed wavelets, the transform can be thought of as an
iterated filter bank (In actuality a constant-q filter bank). Time domain zero mean
implies the basis function must oscillate, and thus is a wave. Whereas the previous
set of conditions are straightforward, regularity is a very complex condition. Regularity is essentially the smoothness of the wavelet, and is important for both frequency
resolution and convergence properties.

Expanding the CWT about (𝑡 = 0, 𝑏 = 0) up to order 𝑛,
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𝑛

1 ∑︁ 𝑝
𝑥 (0)
𝛾(𝑠, 0) = √
𝑠 𝑝=0

∫︁

𝑡𝑝
𝜓(𝑠−1 𝑡)𝑑𝑡 + 𝑂(𝑛 + 1)
𝑝!

(3.26)

𝑤ℎ𝑒𝑟𝑒 : 𝑥𝑝 = 𝑝′ 𝑡ℎ 𝑜𝑟𝑑𝑒𝑟 𝑑𝑒𝑟𝑖𝑣𝑎𝑡𝑖𝑣𝑒 𝑜𝑓 𝑥
𝑂 = 𝑟𝑒𝑚𝑎𝑖𝑛𝑑𝑒𝑟 𝑜𝑓 𝑒𝑥𝑝𝑎𝑛𝑠𝑖𝑜𝑛
The moment of the wavelet, 𝑀𝑝 is then defined as ,
∫︁
𝑀𝑝 =

𝑡𝑝 𝜓(𝑡)𝑑𝑡

(3.27)

Substituting 3.27 into 3.26 yields,

]︂
[︂
′′
′
𝑥 (0)
𝑥𝑛 (0)
1
𝑥 (0)
2
3
𝑛+1
𝑛+2
𝑀1 𝑠 +
𝑀2 𝑠 + ... +
𝑀𝑛 𝑠
+ 𝑂(𝑠 )
𝛾(𝑠, 0) = √ 𝑥(0)𝑀0 𝑠 +
1!
2!
𝑛!
𝑠
(3.28)
From the admissibility condition 3.22, 𝑀0 = 0. Thus if the moments up to 𝑀𝑛 are
set to zero, (3.25) results. This principle, known as vanishing moments, defines the
order of the transform - i.e. if the wavelet has 𝑁 vanishing moments, the approximate
order of the transformation is 𝑁 . As the number of vanishing moments increases, so
does the smoothness of the basis, resulting in decreased localization at high frequencies
(fine resolution at low frequencies, more broad resolution at high frequencies).
Although the CWT offers improved resolution over the STFT [generally] there are
three issues with it,
1. Redundancy
2. Shift Variance
3. Computational Resources
The transform maps a 1-D signal to a highly redundant 2-D space continuously.
To limit the transform the mother wavelet is discretized such that the scale (and by
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result frequency) is dyadic. The discretization of the basis function is similar to the
effect of vanishing moments, in that the dyadic discretization causes fine localization
at high scale (low frequency) and decreased localization at decreasing scale.
While the discretization of the basis function makes the transform practical, it
also causes the transform to become shift variant, meaning that the transform output
depends on when the input occurs. Although this is potentially very problematic,
as the application of SA improves the overall consistency of the ensemble pool it is
assumed that shift variance is minimized as a result of a consistent relative initial
reference. If this were to be found erroneous, then there are alternative wavelet
routines that aim to increase transform shift invariance available, however are not
considered in this work.
The most problematic issue of the transform is by far the resources required to
perform it. Both the STFT and CWT are defined by 𝑛2 transformation variables, an
interesting parallel to non-stationary signal statistical definitions. Unlike the STFT,
where the window modulates, the mother wavelet both modulates and scales. The
scaling function is inherently problematic as an infinite number of scales is required to
analyze to a frequency of zero (dyadic scale backwards from Nyquist). If finer scale
information is required, then the cost of such is increased processing. To mitigate
this the scale is redefined as a function, where each scale can be expressed in terms
of translated smaller scales up to scale 𝑗, however due to this resolution is lost at the
terminally highest scale proportional to the spectrum width of the scaling function
(wider bandwidth means less computation but worse resolution and vice-versa). For
this work, the ensembles are averaged to reduce non-stationarities, however it also
suggests that the resulting signals are of increased value, i.e. classification requires
less individual training states (averages, cycles, etc.). Thus the cost associated with
multi-resolution is traded-off with the inherent benefit of the ensemble averaging.
Spectral generation is performed in MATLAB, restricting the choice of CWT
basis functions - without considering strictly orthogonal or biorthogonal wavelets. A
Morlet basis was used based on its existing application in heart sound analysis [15].
The Morlet basis is essentially a Gaussian windowed sine wave and so it parallels to
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the trigonometric basis of the STFT and related Fourier techniques.
Performance of the CWT is primarily dictated by the design of the scale, 𝑎 as
translation is determined respective of the sampling rate (Minimum time discretization). From the scale, the frequency discretization ultimately results and so through
careful design an optimal frequency spectrum is designed. Through the zero frequency
condition of the transform, the wavelet basis has a bandpass like spectrum. Now considering the scale discretization, the basis will essentially produce a bandpass filter
bank given the design parameters. This filter bank must be carefully designed as
to be inclusive of signal components, at a suitable resolution/discretization, without
being heuristically resource intensive. Given this, three parameters must be designed
for: minimum bandpass center frequency (CF), maximum bandpass CF, and the
discretization of the filter bank.
The in vitro data spectrum approximately spans 20-1000 hz and so the filter bank
must have this minimum bandwidth. Both the minimum and maximum CFs of the
filter bank result from the energy spread of the basis function, the Morlet wavelet. The
maximum CF, 𝜔𝑥 , is modulated by the termination, cutoff percentage, of the lowest
scale wavelet at the Nyquist frequency. Increasing the cutoff moves the CF towards
the Nyquist, and so by decreasing the cutoff the maximum CF can be decreased. The
minimal scale, 𝑎0 is then defined by that CF,

𝑎0 =

𝜔𝑥
𝜋

(3.29)

The maximum scale, 𝑎𝑚𝑎𝑥 , corresponding to the minimum CF, is defined by 3.30.
Whereas minimum scale depended only on wavelet propagation, the maximum scale
is relative to several parameters, making the maximum scale unique to each signal analyzed. Increasing the standard deviation of the wavelet in time causes the minimum
CF to increase as well, thus so long as the the minimum CF is less than the 20 hz
boundary we use the maximum standard deviation to generate the maximum scale.
For example, given a signal of length 9551 samples, a wavelet standard deviation of 14
places the minimum CF at 19.7 hz, satisfying the minimum frequency requirement.
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The resulting filter bank is given in Figure 3-15.

𝑓 𝑙𝑜𝑜𝑟(𝑁 𝑉 𝑙𝑜𝑔2 ( 2𝜎𝑁𝑎 ))

𝑎𝑚𝑎𝑥 = 2

𝑡 0

(3.30)

𝑤ℎ𝑒𝑟𝑒 : 𝑁 𝑉 = 𝑣𝑜𝑖𝑐𝑒𝑠 𝑝𝑒𝑟 𝑜𝑐𝑡𝑎𝑣𝑒
𝑁 = 𝑠𝑖𝑔𝑛𝑎𝑙 𝑙𝑒𝑛𝑔𝑡ℎ (𝑠𝑎𝑚𝑝𝑙𝑒𝑠)
𝜎𝑡 = 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑡ℎ𝑒 𝑤𝑎𝑣𝑒𝑙𝑒𝑡 𝑖𝑛 𝑡𝑖𝑚𝑒
The discretization of the transform is given by 𝑁 𝑉 . Increasing the voices per
octave likewise increases the discretization quantity resulting in higher resolution,
however increased computational cost. As can be seen by Figure 3-15 the density
of the filter bank increases with decreasing frequency (increasing scale) as the scale

Figure 3-15: Morlet wavelet filter bank used to generate the spectra for the in-vitro
acoustics.
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Figure 3-16: Morlet wavelet increased resolution filter bank used to generate the
spectra for the in-vitro acoustics.

is dyadic and propagates from the minimum scale (highest frequency). By limiting
the scale to the minimum bandwidth, specifically the maximum scale, the range
of frequencies (octaves) to discretize over is decreased, allowing for increased voices
without impractical processing cost. The filter bank given in Figure 3-15 is discretized
by 10 voices per octave. Increasing the voices to 40 yields the filter bank of Figure
3-16. Resolution is crucial in identifying events for the purpose of prognostics and
so a moderate 20 (feasible range is 4-48) voices are used in all spectral generations concerning both the in vitro and in vivo acoustics.
The scale is designed similarly for the in vivo data. Since the in vivo data is
characterized by different properties and spectrum elements the resulting filterbank
is different from that produced when analyzing the in vitro acoustics. The in vivo
data is notably characterized by lower frequency components and so the maximum
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Table 3.2: Wavelet scale parameters used in spectra generation.
Data Type
Vitro
Vitro
Vitro
Vivo
Vivo
Vivo

Parameter
Cutoff
Standard Deviation
Voices per Octave
Cutoff
Standard Deviation
Voices per Octave

Value
Affected Scale Parameter
1
Minimum Scale
highest such that CFmin <20 Maximum Scale
20
Scale Discretization
1
Minimum Scale
2
Maximum Scale
20
Scale Discretization

scale of the transform must be comparatively higher than that of the in vitro specific transformation. The parameters used in generating wavelets for both types of
acoustics are provided in Table 3.2.
In order to resolve localized signals the basis function is constrained such that it
vanishes outside of a specified time frame, called the support of the wavelet. This is
problematic near the time boundary of the signal, as no frame exists or which the
wavelet to propagate and so to implement the algorithm the frame is padded with
zeros. This causes discontinuities within these regions that impact the fidelity of
the transformation. The degree to which this occurs increases with increasing scale,
producing a region where these "edge" effects are most prominent, and thus the
transformation coefficients are characterized by increased error. The boundary that
separates the high error region is called the cone of influence (COI). As this work is
interested in the identification of timed events, the input signal must be formed such
that the events will fall inside of the COI, where there is no impact from edge effects.
The COI boundary directly scales with transformation scale, making the CWT very
restrictive to low frequency signals.
Derived spectras of both the faulted and unfaulted in vitro acoustics (similar
boundary conditions) are given in Figures 3-17 and 3-18. The overlayed black lines
of each spectra indicate the COI boundary.
From the spectras several things can be identified. The first of which is the lack
of a defined harmonic band. Due to the constant process frequency of the simulator
scaling is not applied and so the harmonic band would be expected to manifest,
however this is not the case. What appears to occur is that due to the placement of
the stethoscope the spectras exhibit characteristics as if they were determined from
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Figure 3-17: Time-frequency spectra comparison between faulted and unfaulted in
vitro acoustic signal at a state of 106/62 mmHg at 57 BPM with HM2 at 9200 RPM.
Black line indicates COI boundary.
scaled physiological sounds. While not important it does lend support to the occlusion
orientated position of the stethoscope in reference to the in vitro simulator.
In section 2.3 it is discussed that event timing is dependent on the state of the
device (MAP). Figures 3-17 and 3-18, being of consistent states, provide a more detailed analysis of this. At this point it should be noted that the time-frequency images
presented are normalized to their respective maximum intensity (magnitude). Subsequent processing of the images maintains this normalization and so consistent states
are not normalized to a consistent intensity scale. This normalization occurrence is
revisited in the following section.
The time scale of Figures 3-17 and 3-18 are normalized to a [0 1] scale for consistent referencing of the timing at which components occur. A normalized time of 0
100

Figure 3-18: Time-frequency spectra comparison between faulted and unfaulted in
vitro acoustic signal at a state of 106/62 mmHg at 78 BPM with HM2 at 9200 RPM.
Black line indicates COI boundary.
and 1 indicate the beginning of systole (end of diastole) while a normalized time of
.5 indicates the end of systole (beginning of diastole). With the phase partitioned as
such, intensity peaks in [0 .5] are attributed to systole (S1 sounds) while those occurring in [.5 1] are attributed to diastole (S2 sounds). Considering the 57 BPM state
spectra (Figure 3-17) both the S1 and S2 sounds are identifiable. In the unfaulted
signal the S2 is subtly present about 𝑡𝑛𝑜𝑟𝑚 = .8 however when faulted becomes much
more prominent and occurs later. The S1 component also occurs later in systole when
faulted, however is characterized by reduced energy spread about its occurrence. The
faulted intensity scale is greater than that of the healthy spectra intensity scale and
so faulting resulted in a definitively stronger spectral events.
The unfaulted 78 BPM spectra (Figure 3-18) correlates to the unfaulted 57 BPM
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spectra in two primary ways. In comparing the S1 to S2, the S1 components are
relatively more intense. The S1’s of both healthy BPM states are also characterized
by more significant energy spreads (compared to their respective faulted S1’s). When
faulted the 78 BPM state spectra deviates from the trends seen with the 57 BPM state
spectra. Whereas faulting the 57 BPM state delayed sounds, faulting the 78 BPM
state appears to hasten the S1 occurrence. Also inconsistent to the 57 BPM state, the
S2 of the faulted 78 BPM state either appears to have [comparatively] disappeared
or has shifted into the component assumed to be the S1. Additionally, the S1 region
of the faulted 78 BPM state lies right at the boundary of the COI, meaning that if
the entire S1 were desired for analysis, then the signal would have to be altered in a
way that shifts the S1 inward. This can be done by partitioning the signal with cycle
overlap, however this will change the energy spread of the signal since the transform is
shift variant. As such the signals of the in vitro are not modified with any additional
content, termed "padding".
Examining the spectra of the in vivo signal determined from SA (Figure 3-7) an
immediate issue is noticed. The S1 sound (located about the 𝑡𝑛𝑜𝑟𝑚 = .1 region) lies
on the COI boundary, which occurs for several reasons. The mainband of the in vivo
data, 0-50 hz, spans lower frequencies than the in vitro generated signals. Due to this
shift, the in vivo data is more prone to COI effects as the COI scales with transform
scale (increases at low frequency). If the in vivo S1 were shifted up to the mainband
of the in vitro signal, most of the signal would lie outside the COI, however some
content would remain influenced, as was the case with the faulted 78 BPM state S1.
Additionally, the S2 of the in vivo signal occurs much closer to the S1 (𝑡𝑛𝑜𝑟𝑚 = .4
roughly) that was generated in vitro - indicating a deficiency of the simulator. The
signal peak seen at 𝑡𝑛𝑜𝑟𝑚 = .85 appears to be part of the S1 that was truncated off,
however exact determination of this cannot be made based on Figure 3-19 due to the
COI edge effects altering the signal. In order to better examine the signal, the in vivo
data is padded to such that a complete cycle lies outside of the COI boundary. This
is done so by padded each end of the signal with a 40% overlap to the adjacent cycle.
This data is not further evaluated, and so the overlap was chosen based purely on a
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Figure 3-19: Time-frequency spectra of LVAD patient acoustics collected at the aortic
site. Device is the HM2 (9400 RPM), and the ensembling method is SA. Signal period
is limited to one cycle.
value that would appropriately relocate the components.
After padding the S1 is fully outside of the COI, and enough padding was added
such that the next adjacent S1 lies outside the COI (Figure 3-20). The reduction
in edge effects is apparent when comparing S1s, while the spectra originally outside
of the COI is unchanged. What is most important from this spectra (Figure 320) is the comparison between S1 events. The events are identical, indicating that
the SA algorithm perfectly aligned the signal with no misalignment error propagation
occurring. When examining the same spectra derived from varying degrees of UA, and
BUA (Figure 3-21)the benefit of SA over all unscaled algorithms is confirmed. The UA
spectra shows no signs of the second S1 proving that error has significantly propagated
away from the sync point (EKG reference). When restricted to 2% deviation the S2
begins to manifest however more closely resembles the UA signal. At a .5% restriction
the second S1 becomes more visible, however the ensemble has been reduced so much
(73 to 13 cycles) that the entire spectra is altered from the ensemble reduction. The
UA algorithm maintains the most prominent PF band while both BUA routines
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Figure 3-20: Time-frequency spectra of LVAD patient acoustics collected at the aortic
site. Device is the HM2 (9400 RPM), and the ensembling method is SA. Signal period
is extended to an additional 80% of the ensemble mean to show error propagation of
the S1.
increasing degrade it. The UA signal is also characterized by the least noise across
the spectra due to the largest ensemble being utilized for filtering. As the ensemble
is parsed down to align the cycles more closely, the reduction in ensemble size also
reduces the innate filter that ensemble averaging results in. The traces of which are
most noticeable in the 32-512 hz band.
Because of the bandwidth of the in vitro acoustics the majority of the signal is
able to avoid influence from the COI. If the in vitro acoustics were characterized by
the same bandwidth as the in vivo sound additional analyses would be necessary to
determine spectral padding, however at this point remains unnecessary given the shift
variance of the algorithm. Using the SA routine, extremely high fidelity spectras are
achievable, from which events can be easily identified, although not consistently. The
lack of S2 manifestation in the faulted spectra of Figure 3-18 is concerning as it is a
clear deviation from the signal components expressed in the in vivo spectra.
A potential explanation for the omission of the S2 (along with timing variation) is
104

Figure 3-21: Time-frequency spectra of LVAD patient acoustics collected at the aortic
site. Device is the HM2 (9400 RPM), and the ensembling method is both UA (top)
and BUA (middle and bottom). Signal period is extended to an additional 80% of
the ensemble mean to show error propagation of the S1.

the location of the stethoscope. The occlusion element is implemented down the graft
line of the VAD, meaning that there is a time delay between when water exits the
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VAD and enters the blockage element. Along with the phase dependence on state,
the timing delay may also depend on the state. Coupled together these two characteristics could feasibly create a very nonlinear relationship between sound timing
and state, one of which could cause sound omission, relocation, and potentially generation nonlinearities and non-stationarities. Acquiring acoustics at the obstruction
site followed a diagnostic reasoning - probe at the expected fault site however given
this finding a more immediate location is also examined to determine if the location
affects the observed event timing.
When acquired directly at the VAD, the in vitro acoustic spectra is significantly
different from the obstruction based spectra. The first observation is that the PF band
is one of the two most prominent components, the other being the S1 sound located
about 𝑡𝑛𝑜𝑟𝑚 = .25. The other observation is made after comparing several same
pressure state healthy-faulted data sets. Even though the sample set is statistically
insignificant, there appears to be a potential indicator of condition present. Across
12 same state tests of varied condition, the S1 component occurs earlier in 10 of the
12 spectras. While a striking observation, this occurrence was not further studied
due to time constraints and due to the contour of the spectra at the this location.
The spectra is characterized by a prominent PF band and shows no signs of an S2,
both of which conflict with the in vivo spectra. To remain consistent with the in vivo
acoustics, sounds are not further collected at the VAD surface, However should there
be a location on the body which manifests sounds similar to this, further testing at
the VAD surface would be strongly merited. This may potentially occur if sounds
are acquired directly at the VAD surface of a patient, rather than at the valvular
auscultation sites.

3.3

Feature Generation

In the time domain, the S1 and S2 of both the in vivo and in vitro acoustics can be
generally identified by the two highest magnitude waves/components of the cardiac
cycle. While generally holding true, it is also seen in Figure 2-21 that this varies
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Figure 3-22: Time-frequency spectra of in vitro LVAD acoustic acquired at VAD
surface. Signal is averaged using UA algorithm. VAD is operating at 9400 RPM at a
state of 107/63 mmHg at 78 BPM.

depending on both state and health (unfaulted/faulted) for the in vitro data, for
which the health relationship correlates to Figure 1-2 for physiological sounds (cannot
confirm the state correlation). In the frequency domain the simulated acoustics are
characterized by the dual peak components shown in Figures 2-19 and 2-20, which
differs from the singular peak seen in the respective in vivo spectrums. Using the
time-frequency domain representation resultant from the CWT, not only are the S1
and S2 defined by intensity peaks, the localization and energy spread of the events
are shown - which can be leveraged for classification.
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Due to the timing dependence on state it is impossible to identify a consistent
region in the signal spectra, called the region of interest (ROI), which across the
HMAPR indicates a condition change (healthy vs. faulted). Each state of the system
manifests uniquely in the resulting spectra in the form of energy spreads, preventing
visual discernment of indicators from state dependent components, variation components, etc. Given the inability to manually determine indicators or the ROI, the location of the indicators relative to consistently identifiable events of the signal/spectra
are assumed.
When parsed by the trigger signal, no additional cycle data is partitioned onto
the ensemble averaged in vitro signal in order to eliminate the potential shift variance
effects of the CWT. As a result of this, not all of the resulting cycle spectra can be
used due to the transform edge error propagation (defined by the COI). The choice
of non-partitioning also has the effect of maintaining a relative time reference frame
across the ensemble averages. When normalized to a [0 1] space, the endpoints, 0 and
1, indicate trigger peaks, or physically the end of diastole/beginning of systole. The
midpoint of the scale, .5 indicates the end of systole/beginning of diastole. If each
ensemble were partitioned with additional data, assuming each ensemble is not of the
same length and period, the only phase change that could be consistently identified is
the end of systole if the partitioning is symmetric (equal amounts at each endpoint).
The identification of phase is significant because at minimum the spectra can be
analyzed in terms of systole and diastole independently rather than its entirety. If not
for edge effects the normalized time frames of systole and diastole would be [0 .5] and
[.5 1] respectively. To avoid edge error propagation the the frequency frame of the
ROI must first be determined so that the maximum COI effect can be quantified. As
discussed when generating the wavelet coefficient matrix, edge effects become more
significant with increasing scale. Thus, as with the case with the in vivo spectra, as
the scale increases more of the signal becomes corrupted. To maintain the widest time
frame possible, the lowest frequency of the ROI must be maximized such that the
COI does not impact significant content. The mainband of the in vitro data is defined
by the bandwidth of 50 hz to 150 hz, and so this is used to bound the ROI. The ROI
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must inclusive of this bandwidth and so the highest dyadic integer that is inclusive of
this region (32 hz) is chosen as the lower bound. The relationship between COI and
wavelet basis is complex, depending on basis support (propagation) along with the
transform variables. Analytically defining the COI boundary for a desired frequency
is difficult. This value is instead found empirically by generating the COI for multiple
BPM data sets. The COI is seen to increase (in restriction) with increasing BPM so
by analyzing the 78 BPM data the maximum boundary of the COI is determined. At
a frequency of 31.94 hz a maximum COI normalized time boundary of .0546 results,
which then is rounded down to .05 for computation.
With the COI boundary identified, the respective phase time frames are modified
as the COI restriction is symmetric about the spectra time scale midpoint (another
reason for no partitioning). The ROI minimum frequency bound is constrained to
be 32 hz in the COI analysis, leaving only the ROI maximum frequency bound to
be determined. The maximum bandwidth of the mainband is defined as 150 hz, at
which point the PF band of the HM2 occurs for the in vitro tests. As shown in
the spectrums of Figure 3-10 and the time-frequency spectras of Figures 3-17 - 3-18
ensemble averaging results in a warped PF band. The degree to which this occurs
is assumedly related to the degree of misalignment (in unscaled algorithms) or the
degree to which the data was resampled and shifted (in scaling algorithms). To avoid
introducing this inconsistency into the ROI the maximum frequency of the region is
bounded at maximum to be 150 hz.
Using the phase bounds as defined above five ROIs are defined, as given in Table
3.3. The first region, ROI 1, is the performance benchmark of the others, being
that it is only frequency bounded (time bounded only by COI restriction, not by
any empirical/theoretical significance). ROI 1 is expected to perform the worst of
any region, in determining condition as it is the largest, which makes its derived
parameters prone to influence from redundant space. Both ROI 2 and 3 (Figure
3-23) are specific to systole and diastole respectively, which eliminates parameter
biasing from the adjacent phase. These regions can further be decomposed however
requires event timing analysis, which is how ROI 4 and 5 are determined.
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Table 3.3: ROI boundaries developed from phase and sound occurrence.
Minimum Maximum
Minimum
Maximum
ROI ID
Time [-]
Time [-]
Frequency [Hz] Frequency [Hz]
1
.05
.95
32
150
2
.05
.5
32
150
3
.5
.95
32
150
4
.1
.4
32
150
5
.7
.95
32
150

To determine the regions within ROIs 2 and 3 in which the S1 and S2 most frequently occur the timing of when the peak signal value occurs in systole and diastole
are examined. Given a low simulated heart rate the data trends linearly with pressure,
with both the S1 and S2 occurrence converging to the beginning of systole (Figure 324). There isn’t a necessarily clear differentiation between faulted and healthy sound
occurrences, however faulted sounds may appear to occur earlier than healthy sounds.
When the simulated heart rate is increased this trend, while it still roughly exists, is
characterized by increased deviation and outliers, occurrences which span a greater

Figure 3-23: Phase ROIs (2 and 3) parsed from in vitro generated acoustic spectra of
state 106/62 mmHg at 57 BPM. Note the image intensity scale normalization effects
of parsing.
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time range, and S2 sounds that occur at the very end of diastole (Figure 3-25). When
examining the remaining two test sets (57 and 67 BPM) the S2 timing appears to
roughly scale with heart rate (increasing rate yields later occurring sounds). Occurrence deviation on the other hand does not follow such a trend. The approximated
boundaries of the sounds occurrences are provided in Table 3.3.
S1 sounds are generally limited to the space of [.1 .4] while the S2 most commonly
occurs within [.7 1]. Even though the sounds primarily lie within these regions there
are non-outlier instances of sounds occurring outside of these bounds, most typically
with the 78 and 57 BPM data sets, about the COI restricted boundaries. As a result,
the ability to classify the condition of those points may be affected as their occurrences
cannot be leveraged, unless the region is augmented with another in which condition
can be discerned, without skewing the existing classification potential of the original
region.
The ROIs are 2D mappings of the objective signal, they can be converted into
images from which statistical parameters can be computed, resulting in the classification features. The ROIs are each converted into a grayscale image and a binary

Figure 3-24: In vitro occurrence of S1 and S2 sounds at 47 BPM. Pressure axis in
normalized by systolic pressure.
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Figure 3-25: In vitro occurrence of S1 and S2 sounds at 78 BPM. Pressure axis in
normalized by systolic pressure.
(black and white) image as each has specific parameters that can be extracted. From
the grayscale image 13 texture based parameters are extracted while 18 shape based
parameters result from the binary image. Table 3.3 provides all image based features
extracted. The compiled vector of all 31 parameters is called the feature vector, and
is used as the input to the classifier. The individual parameters are computed using
the "regionprops" algorithm in MATLAB in which the provided listed parameters are
numerically computed for images.
When parsing the spectra into the five ROIs, each resulting matrix image is renormalized according to the maximum element of the parsed ROI matrix. Due to this
the resulting ROI image (and eventual grayscale/binary) differs in appearance from
Table 3.4: Summary of boundaries of S1 and S2 occurrences for test data set simulated
heart rates. Boundaries are approximated to omit outlier points.
S1 Occurrence
S1 Occurrence
S2 Occurrence
S2 Occurrence
Heart Rate
Minimum Bound Maximum Bound Minimum Bound Maximum Bound
[BPM]
[t/tmax]
[t/tmax]
[t/tmax]
[t/tmax]
47
.1
.35
.7
.95
57
.1
.4
.7
1
67
.125
.35
.8
1
78
.1
.4
.8
1
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Table
ID
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31

3.5: Parameters extracted from images of ROI.
Parameter
Type
Image
Mean
Texture Grayscale
Standard Deviation
Texture Grayscale
Skewness
Texture Grayscale
Kurtosis
Texture Grayscale
Contrast Mean
Texture Grayscale
Correlation Mean
Texture Grayscale
Energy Mean
Texture Grayscale
Homogeneity Mean
Texture Grayscale
Contrast Range
Texture Grayscale
Correlation Range
Texture Grayscale
Energy Range
Texture Grayscale
Homogeneity Range
Texture Grayscale
Entropy
Texture Grayscale
Area
Shape
Binary
Centroid X
Shape
Binary
Centroid Y
Shape
Binary
Bounding Box X
Shape
Binary
Bounding Box Y
Shape
Binary
Bounding Box Width Shape
Binary
Bounding Box Height Shape
Binary
Major Axis Length
Shape
Binary
Minor Axis Length
Shape
Binary
Eccentricity
Shape
Binary
Orientation
Shape
Binary
Convex Area
Shape
Binary
Filled Area
Shape
Binary
Extreme Right Y
Shape
Binary
Equivalent Diameter Shape
Binary
Solidity
Shape
Binary
Extent
Shape
Binary
Perimeter
Shape
Binary
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Figure 3-26: Sound occurrence ROIs (4 and 5) parsed from in vitro generated acoustic
spectra of state 106/62 mmHg at 57 BPM. Note the image intensity scale normalization effects of parsing.

how it appears in reference to the entire spectra. Given the spectra of Figures 3-23
and 3-26 the peak intensity component is located about the S1. When parsing into the
individual ROIs, those that contain the S1 (ROI 2 and 4) maintain their appearance as
they are intensity normalized to the same value. However when the spectra maximum
is excluded from the ROI, the resulting region image is re-normalized according to
its maximum intensity. This most commonly occurs when parsing ROI 3 and 5, due
to the absence of the S1. Due to this the S2, if it exists in this region, becomes
pronounced. This however is not considered an algorithm deficiency as ROIs are only
consistently used and compared against the same ROI, i.e. ROI 2 is only compared
against ROI 2 and so image normalization based on region is appropriate.
The ROI matrix is converted to a grayscale image using a discretization of 256
levels with a floor/ceiling (max minimum value) of +- 8. Each element of the matrix
represents an image pixel and so the size of the image matches the matrix dimensions.
The grayscale image is then used to convert to binary by determining the average
gray level of the grayscale image, and using that threshold to convert to black and
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white, with any conversion artifacts (random spots) being removed from the binary
image. After each image is generated they are then resized due to the discretization
of the wavelet coefficients. The sampling rate of the input signal (to the CWT)
matches the time discretization of the coefficients and so the time axis length scales
proportionally with sampling rate. The scale (and by result frequency) discretization
however is dyadic and bounded specifically by the filterbank design (Table 3.2). For
example, given the bounds on the S1 region, a 3343x66 matrix is formed. When
converted to an image it has a 50:1 width-height ratio, skewing it and its associated
parameters. To adjust for the discretization scheme the images are resized to a square
𝑛𝑥𝑛 pixel frame. After empirical trials, a 400𝑥400 frame was found to be practical as
further increasing the dimension did not elicit any further classification differences.
It is true that resizing does affect the parameters extracted from the images, however
none of the parameters are only dependent on image size, i.e. no parameter becomes
redundant or obsolete from resizing. The resized grayscale and binary versions of the
ROIs of Figure 3-23 and 3-26 are given in Figures 3-27 and 3-28 respectively.
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Figure 3-27: Conversion of phase ROIs (2 and 3) parsed from in vitro generated
acoustic spectra of state 106/62 mmHg at 57 BPM to grayscale and binary. Note the
image intensity scale normalization effects of parsing.
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Figure 3-28: Conversion of sound occurrence ROIs (4 and 5) parsed from in vitro
generated acoustic spectra of state 106/62 mmHg at 57 BPM to grayscale and binary.
Note the image intensity scale normalization effects of parsing.
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Chapter 4
Results
Classification of the healthy and unhealthy data is performed using a support vector
machine (SVM), with the feature vector used as the input. The SVM is a type of
supervised (generally) machine learning algorithm. The algorithm essentially creates
an 𝑛 − 1 hyperplane through an 𝑛 dimensional space such that the space from the
plane to two distinct data classes is maximized. This is also called the maximum
margin hyperplane. Thus when new data is introduced, it can be binned to a class
depending on where it falls with respect to the hyperplane. The vectors used to
directly develop the maximum margin hyperplane are called the support vectors.
Often two data sets are not linearly separable in their given space and require
a more complex classification approach. When n dimensional linear classification
may not be possible, higher space domains (n+) presumably make such classifications possible. In order to do so an SVM ’kernel trick’ transforms data to a higher
order space using a kernel function to reduce computational resources. The kernel
function simply allows for mapped space computations to be performed in terms of
the original space variables, specifically dot product computations. There are several
feasible kernel functions that can be used for higher order classification, however the
appropriateness of the kernel is not guaranteed for all feasible functions. The SVM is
chosen over alternative machine learning algorithms as it is assumed that the acoustic
feature data would be nonlinearly separable, which the SVM can efficiently handle.
Additionally the feature vector is relatively small, and so more complex classifiers and
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machine learning algorithms are not required.

4.1

Classifier Performance

Prior to classification three model parameters must be determined along with a preprocess of the feature vector. The features that are developed from the ROIs span a
large numerical range. This being the case, there is a disparity in relative parameter values. For example convex area is roughly 1,000,000 times larger in magnitude
that correlation range, which if nominally used would skewly weight convex area.
The feature vectors of the SVM are normalized to a [-1 1] space to standardize each
parameter to equal weighting. This is consistent across all tests.
The three model parameters that must be determined are kernel function, kernel
scale, and box constraint. Both kernel parameters define the function used to transform the feature space while the box constraint alters misclassification cost. The
larger the box constraint the more strictly the training space is separated, requiring
increased resources to do so. The choice of model parameters varies based on the ROI
and feature selection resulting in several unique combinations to be determined.
Model parameters are determined through a 10 fold cross validation optimization
of each unique model. In the optimization scheme the training set is randomly partitioned into 10 subsets. An SVM model is trained on 9 randomly selected subsets,
while the tenth is used to test the resulting model. This is iterated ten times resulting
in an average cross validation error of the model. Both the kernel scale and box constraint are optimized against this value for a given set of iterations or until parameter
convergence is met. The optimization scheme used to determine the parameters is a
Bayesian scheme which assumes a Gaussian process and so the final model parameter,
the kernel function, is constrained to be the Gaussian kernel. While the optimization
scheme permits minimal model definition a priori it also constrains the model space to
the training data based on minimal cost. Because of this the classifier is expected to
perform well only in instances in which the testing feature vectors do not vary from
the training feature vectors space, assuming that the classification space is tightly
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bounded to the training vectors. This optimization outcome is highly impractical
for physiological signal classification due to the changes a patient may undergo in
between classification routines, i.e. baselined at time of implantation, then tested for
thrombosis several months later when the patient’s state (MAP and heart rate) has
changed. In order to compare models three metrics are compiled per model validation
(test), score, positive predictive value (PPV), and negative predictive value (NPV).
Score is the total percentage of correct classifications while PPV and NPV are the correct healthy (unfaulted) classifications and correct unhealthy (faulted) classifications
respectively. Classifier nomenclature is as follows,
1. BPMA classifier: model trained on one constant BPM
2. BPMB classifier: model trained on two constant BPMs
3. BPMC classifier: model trained on three constant BPM
4. BPMD classifier: model trained on four (all) constant BPMs
Classifiers are evaluated absolutely by their kfold error, score, PPV, and NPV.
Several metrics are developed for comparisons between models derived from different
ROIs. These parameters are:
1. BPMA Common Predictive Value (BPMA-CPV): average value of BPMA model
scores tested with the same BPM used in training.
2. BPMA Foreign Predictive Value (BPMA-FPV): average value of BPMA model
scores tested with different BPM used in training.
3. BPMD Common Predictive Value (BPMD-CPV): average value of BPMD model
scores tested with constant BPM set.
4. BPMD Variable Predictive Value (BPMD-VPV): BPMD model score tested
with variable BPM set.
5. BPMC Foreign Predictive Value (BPMC-FPV): average value of BPMC model
scores tested with different BPM used in training.
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6. BPMC Variable Predictive Value (BPMC-VPV): average value of BPMC model
scores tested with variable BPM set.
These parameters are chosen to quantify several model abilities, namely the potential to classify states of which it is trained on (Common Predictive Value), the
potential to classify states that it is not trained with (Foreign Predictive Value), and
finally the potential to classify states similar to physiological signals (Variable Predictive Power). BPMA and BPMD are both used as they are expected to the respective
worst and best performance training spaces due to their spans. The BPMC derived
models are chosen to evaluate predictive performance based on how training set deviations affect performance as compared to the expected best training space, BPMD.
Performance metrics for all image feature only classification iterations are given in
Table 4.1.
The performance of the baseline classifiers (Table 4.1), those derived from ROI 1
image features, are found to be very dependent on the training space, as is expected.
BPMA-CPV is significantly higher than BPMA-FPV with few exceptions (1.12).
Given the most comprehensive training set (1.17-1.21 - BPMD) the model scores per
each testing set are higher than the related BPMACPV iterations (with the 67 BPM
exception again). This is an interesting finding as it was expected that the BPMA
models (1.1-1.16) would result in the global highest scores. The kfold values of the
models supports this assumption, however the scores do not. This is believed to stem
from either the optimization scheme or the training space modification.
Due to the HMAPR variation induced during experimental testing it is likely that
a portion of the testing states are not in the near vicinity of a training point (assuming
same BPM sets). When the classifier is trained by this set, due to the optimization
scheme the space is constrained for optimality relative to the training set, meaning
that the space is constrained as tightly as permitted to the training space. Given
that the test state is not in the immediate space of the training state the model
results in misclassification, due to training space over-constraining. When additional
states are introduced during training two possible events may occur which explain the
score-kfold inconsistency. Given that the states of the training space are relatively
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Table 4.1: Classification results using ROI 1 image features. Training and testing set
nomenclature refers to the simulated BPM of the set.
Training Kfold Error Testing Score PPV NPV
ID
Set
[%]
Set
[%]
[%]
[%]
1.1
47
96.7
93.3 100.0
1.2
57
23.3
43.3
3.3
47
0.50
1.3
67
65.0
100.0 30.0
1.4
78
26.7
0.0
53.3
1.5
47
48.3
0.0
96.7
1.6
57
80.0
60.0 100.0
57
5.00
1.7
67
15.0
0.0
30.0
1.8
78
73.3
100.0 46.7
1.9
47
51.7
100.0
3.3
1.10
57
48.3
83.3
13.3
67
0.50
1.11
67
68.3
93.3
43.3
1.12
78
76.7
63.3
90.0
1.13
47
50.0
100.0
0.0
1.14
57
63.3
93.3
33.3
78
3.50
1.15
67
46.7
50.0
43.3
1.16
78
70.0
60.0
80.0
1.17
47
96.7
93.3 100.0
47
1.18
57
88.3
76.7 100.0
57
1.19
4.00
67
56.7
86.7 100.0
67
1.20
78
80.0
83.3
26.7
87
1.21
Variable 85.0
83.3
76.4
1.22
57 67
47
71.7
96.7
46.7
5.00
1.23
Variable 85.0
83.3
86.7
78
1.24
47 67
57
66.7
86.7
46.7
3.50
1.25
Variable 85.0
96.7
73.3
78
1.26
47 57
67
36.7
10.0
63.3
5.00
1.27
Variable 63.3
40.0
86.7
78
1.28
47 57
78
68.3
90.0
46.7
5.00
1.29
67
Variable 86.7
90.0
83.3
similar and of the same class (health condition), the optimization routine may project
the sets to the same approximate space during the kernel transform resulting in both
sets being used as support vectors, thus increasing the space span. The second theory
essentially states the opposite of the first, when projected the states of opposite classes
align resulting in the separation boundary becoming more under-constrained.
The BPMC models classify the variable set more accurately than the foreign sets
(VPV > FPV) as is expected. The foreign sets are located at BPM states of maxi123

mum margin away from the training space, thus are the worst case test sets for the
BMPC models, assuming maximum margin/deviation yield maximum misclassification. Because the training data sets are discretized by 10 BPM increments, assuming
uniform distribution, the variable set will be within <5 BPM of a training state over
75% of the training space, while over the remaining space will be within <10 BPM.
The foreign set is consistently at the maximum margin of 10 BPM deviation and so
we expect the PV of this set to be significantly lower, which it is. In reference to the
BPMD models, the BPMC models perform very similarly in terms of VPV due to
the additional BPM set of the BPMD model altering only the 25% 10 BPM margin
to a 5 BPM margin - a relatively small change with little results. The classifiers are
Table 4.2: Classification results using ROI 2 and 3 image features. Training and
testing set nomenclature refers to the simulated BPM of the set.
ID
2.1
2.2
2.3
2.4
2.5
2.6
2.7
2.8
2.9
2.10
2.11
2.12
2.13
2.14
2.15
2.16
2.17
2.18
2.19
2.20
2.21
2.22
2.23
2.24
2.25
2.26
2.27
2.28
2.29

Training
Set

47

57

67

78
47
57
67
78
57 67
78
47 67
78
47 57
78
47 57
67

Systolic Phase
Kfold
Testing
Error
Set
[%]
47
57
0.00
67
78
47
57
6.00
67
78
47
57
3.00
67
78
47
57
5.00
67
78
47
57
5.88
67
78
Variable
47
6.00
Variable
57
4.33
Variable
67
4.67
Variable
78
3.50
Variable

Classifier (ROI 2)
Score PPV
[%]
[%]

NPV
[%]

100.0
40.0
25.0
51.7
66.7
91.7
25.0
85.0
5.0
30.0
90.0
35.0
50.0
50.0
58.3
23.3
95.0
91.7
65.0
60.0
48.3
66.7
45.0
48.3
48.3
30.0
48.3
66.7
50.0

100.0
76.7
23.3
100.0
33.3
100.0
13.3
73.3
10.0
20.0
86.7
30.0
0.0
0.0
16.7
30.0
100.0
96.7
46.7
56.7
23.3
36.7
16.7
20.0
23.3
46.7
36.7
36.7
16.7

100.0
3.3
26.7
3.3
100.0
83.3
36.7
96.7
0.0
40.0
93.3
40.0
100.0
100.0
100.0
16.7
90.0
86.7
83.3
63.3
73.3
96.7
73.3
76.7
73.3
13.3
60.0
96.7
83.3
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Diastolic Phase Classifier (ROI 3)
Kfold
Testing Score PPV NPV
Error
Set
[%]
[%]
[%]
[%]
47
98.3
96.7 100.0
57
33.3
66.7
0.0
1.00
67
50.0
100.0
0.0
78
31.7
33.3
30.0
47
43.3
86.7
0.0
57
68.3
36.7 100.0
9.50
67
38.3
70.0
6.7
78
55.0
83.3
26.7
47
50.0
100.0
0.0
57
38.3
73.3
3.3
4.00
67
53.3
86.7
20.0
78
55.0
100.0 10.0
47
13.3
13.3
13.3
57
51.7
46.7
56.7
7.00
67
53.3
20.0
86.7
78
53.3
56.7
50.0
47
96.7
93.3 100.0
57
76.7
56.7
96.7
7.88
67
53.3
80.0
26.7
78
48.3
73.3
23.3
Variable 70.0
83.3
56.7
47
31.7
53.3
10.0
10.33
Variable 76.7
86.7
66.7
57
43.3
66.7
20.0
4.00
Variable 48.3
43.3
53.3
67
68.3
63.3
73.3
8.83
Variable 71.7
86.7
56.7
78
51.7
80.0
23.3
6.83
Variable 68.3
96.7
40.0

slightly skewed towards PPV rather than NPV (75.7% vs. 68.9%).
When the classifier is developed from the phase specific ROIs (ROI 2 and 3) the
trends previously seen in the baseline classifier become less prominent (Table 4.1).
Both BPMD model (systolic and diastolic) CPV values roughly equal the BPMACPV values, whereas before the they had been greater. Additionally, scores derived
from both phase classifiers are comparatively lower on average to the baseline classifier indicating that both phases contribute some classification ability. The diastolic
classifiers are more accurate compared to the related systolic classifiers with less score
deviation. The bias towards PPV remains in both phase classifiers, however due to
the comparatively lower scores, the bias becomes more significant. The diastolic classifiers also performed much more accurately that the systolic models when classifying
the variable data states. This is believed to occur due to the S2 timing spread being
greater than that of the S1 respective of the variable BPM set, allowing the classifier
to constrain to a larger space.
The S1 and S2 classifiers (those derived from ROI 4 and 5) perform generally
the same as the phase derived classifiers. Both are characterized by the same bias
to PPV and the S1 outperforms the S2 on average with the exception of testing
against the variable test set just as was seen in comparing the phase classifiers. The
S1 score metrics correlate very strongly with that of the systolic classifier, however
the S2 metrics deviate from those of the related diastolic models, most notably in
reference to VPV and FPV. The S2 classifier scores lower in these two categories,
which is justifiable as the S2 ROI spans roughly half the time space as the diastolic
ROI, meaning that the outlier points to this region cannot be used for classification.
Similarly, the S1 performing better than the S2 can also be explained by the region
span difference, being that the S2 ROI is reduced by 44% of the original phase whereas
the S1 ROI is reduced by 33%.
Both the phase and sound classifiers share the common traits of performing significantly worse than the baseline classifier on average and having a trade-off between
VPV and CPV. The reduction in spectra space clearly impacts classification potential, while trade-off implies that the diastolic phase specifically impacts classification
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Table 4.3: Classification results using ROI 4 and 5 image features. Training and
testing set nomenclature refers to the simulated BPM of the set.
ID
2.1
2.2
2.3
2.4
2.5
2.6
2.7
2.8
2.9
2.10
2.11
2.12
2.13
2.14
2.15
2.16
2.17
2.18
2.19
2.20
2.21
2.22
2.23
2.24
2.25
2.26
2.27
2.28
2.29

Training
Set

47

57

67

78
47
57
67
78
57 67
78
47 67
78
47 57
78
47 57
67

S1 Derived Classifier (ROI
Kfold
Testing Score PPV
Error
Set
[%]
[%]
[%]
47
100.0 100.0
57
45.0
10.0
1.00
67
16.7
16.7
78
65.0
36.7
47
48.3
0.0
57
88.3
80.0
8.50
67
35.0
66.7
78
65.0
93.3
47
1.7
0.0
57
38.3
63.3
1.50
67
90.0
90.0
78
26.7
33.3
47
50.0
100.0
57
41.7
83.3
5.50
67
91.7
100.0
78
41.7
46.7
47
90.0
80.0
57
88.3
83.3
5.88
67
91.7
90.0
78
53.3
60.0
Variable 46.7
76.7
47
61.7
90.0
6.67
Variable 45.0
70.0
57
31.7
63.3
3.67
Variable 40.0
63.3
67
55.0
36.7
5.33
Variable 55.0
63.3
78
51.7
80.0
4.00
Variable 50.0
80.0

4)
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NPV
[%]
100.0
80.0
16.7
93.3
93.3
96.7
3.3
36.7
3.3
13.3
90.0
20.0
0.0
0.0
83.3
36.7
100.0
93.3
93.3
46.7
16.7
33.3
20.0
0.0
16.7
73.3
46.7
23.3
20.0

S2 Derived Classifier (ROI
Kfold
Testing Score PPV
Error
Set
[%]
[%]
[%]
47
98.3
96.7
57
40.0
70.0
1.00
67
48.3
36.7
78
40.0
20.0
47
55.0
93.3
57
75.0
53.3
5.00
67
45.0
86.7
78
58.3
100.0
47
21.7
43.3
57
41.7
70.0
5.00
67
53.3
76.7
78
53.3
73.3
47
18.3
30.0
57
46.7
70.0
4.00
67
60.0
83.3
78
55.0
73.3
47
93.3
93.3
57
71.7
60.0
7.88
67
65.0
86.7
78
45.0
83.3
Variable 60.0
66.7
47
40.0
50.0
10.17
Variable 58.3
60.0
57
40.0
76.7
2.83
Variable 58.3
66.7
67
33.3
10.0
8.00
Variable 53.3
50.0
78
53.3
96.7
6.67
Variable 63.3
73.3

5)
NPV
[%]
100.0
10.0
60.0
60.0
16.7
96.7
3.3
16.7
0.0
13.3
30.0
33.3
6.7
23.3
36.7
36.7
93.3
83.3
43.3
6.7
53.3
30.0
56.7
3.3
50.0
56.7
56.7
10.0
53.3

Table 4.4: Classification results using combined image features (ROI 2+3 and ROI
4+5). Training and testing set nomenclature refers to the simulated BPM of the set.
ID
2.1
2.2
2.3
2.4
2.5
2.6
2.7
2.8
2.9
2.10
2.11
2.12
2.13
2.14
2.15
2.16
2.17
2.18
2.19
2.20
2.21
2.22
2.23
2.24
2.25
2.26
2.27
2.28
2.29

Training
Set

47

57

67

78
47
57
67
78
57 67
78
47 67
78
47 57
78
47 57
67

Phase Augmented Classifier
Kfold
Testing Score PPV NPV
Error
Set
[%]
[%]
[%]
[%]
47
98.3
96.7 100.0
57
33.3
63.3
78.3
0.50
67
78.3
100.0 56.7
78
28.3
30.0
26.7
47
41.7
0.0
83.3
57
85.0
70.0 100.0
5.50
67
8.3
0.0
16.7
78
73.3
100.0 46.7
47
26.7
53.3
0.0
57
33.3
63.3
3.3
3.00
67
63.3
100.0 26.7
78
43.3
40.0
46.7
47
33.3
66.7
0.0
57
60.0
100.0 20.0
5.00
67
56.7
86.7
26.7
78
48.3
53.3
43.3
47
98.3
96.7 100.0
57
93.3
87.7 100.0
4.88
67
78.3
86.7
70.0
78
65.0
73.3
56.7
Variable 65.0
73.3
56.7
47
28.3
3.3
53.3
6.17
Variable 66.7
66.7
66.7
57
53.3
90.0
16.7
2.67
Variable 61.7
76.7
46.7
67
40.0
0.0
80.0
5.17
Variable 46.7
46.7
46.7
78
76.7
96.7
56.7
3.17
Variable 73.3
90.0
56.7
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Sound Augmented
Kfold
Testing Score
Error
Set
[%]
[%]
47
98.3
57
38.3
0.50
67
50.0
78
45.0
47
73.3
57
83.3
3.50
67
21.7
78
60.0
47
6.7
57
36.7
1.50
67
91.7
78
31.7
47
50.0
57
50.0
5.50
67
66.7
78
45.0
47
90.0
57
86.7
5.25
67
81.7
78
65.0
Variable 58.3
47
48.3
5.83
Variable 55.0
57
40.0
3.50
Variable 50.0
67
66.7
6.00
Variable 51.7
78
71.7
3.17
Variable 73.3

Classifier
PPV
[%]

NPV
[%]

96.7
76.7
100.0
16.7
100.0
66.7
23.3
100.0
13.3
73.3
100.0
20.0
100.0
100.0
100.0
53.3
80.0
80.0
86.8
83.3
60.0
0.0
43.3
80.0
70.0
56.7
53.3
100.0
83.3

100.0
0.0
0.0
16.7
46.7
100.0
20.0
20.0
0.0
0.0
83.3
43.3
0.0
0.0
33.3
36.7
100.0
100.0
93.3
76.7
46.7
96.7
66.7
0.0
30.0
76.7
50.0
43.3
63.3

Table 4.5: Classification results using combined image features (ROI 2+3 and ROI
4+5) with a discretization, n = 2. Training and testing set nomenclature refers to
the simulated BPM of the set.

ID
4.1
4.2
4.3
4.4
4.5
4.6
4.7
4.8
4.9
4.10
4.11
4.12
4.13

Training
Set
47
57
67
78
57 67
78
47 67
78
47 57
78
47 57
67

Phase Augmented Classifier
(n = 2 Discretization)
Kfold
Testing Score PPV NPV
Error
Set
[%]
[%]
[%]
[%]
47
100.0 100.0 100.0
57
91.7
83.3 100.0
4.63
67
56.7
93.3
20.0
78
73.3
100.0 46.7
Variable 76.7
86.7
66.7
47
68.3
70.0
66.7
7.33
Variable 85.0
90.0
80.0
57
58.3
100.0
1.7
3.33
Variable 66.7
83.3
50.0
67
58.3
100.0 16.7
5.00
Variable 65.0
96.7
33.3
78
76.7
90.0
63.3
3.33
Variable 68.3
93.3
43.3

Sound Augmented Classifier
(n = 2 Discretization)
Kfold
Testing Score PPV NPV
Error
Set
[%]
[%]
[%]
[%]
47
96.7
96.7
96.7
57
85.0
73.3
96.7
5.00
67
55.0
83.3
26.7
78
68.3
76.7
60.0
Variable 76.7
93.3
60.0
47
45.0
36.7
53.3
5.00
Variable 73.3
73.3
73.3
57
46.7
66.7
26.7
3.33
Variable 68.3
80.0
56.7
67
69.0
84.0
54.0
6.13
Variable 75.0
76.7
73.3
78
68.3
93.3
43.3
3.66
Variable 66.7
93.3
40.0

of the variable set. Given these determinations the phase and occurrence models can
be seen as complimentary (systole compliments diastole, S1 compliments S2). To
elicit classifiers with characteristics of the compliment set, phases ROI features are
augmented together, and sound ROI features are augmented together. The phase
augmented classifier is trained on the image features of ROI 2 and 3 (the phase regions), while the sound augmented classifier is trained with the image features of ROI
4 and 5 (the sound regions), resulting in training vectors of length 𝑛 = 62 for each
augmented classifier.
The augmented classifiers both perform better on average as compared to the models derived from either of their individual augmented ROIs. The metrics of augmented
classifiers are either greater than those of the individual ROIs, or approximately the
maximum of either. This lessens the bias towards PPV, however augmented models
still are characterized by PV skewness. While the models are an improvement over
their components, both still underperform compared to the baseline classifier (10%
mean score disparity). In order to attempt to improve performance, each augmented
classifier ROI is discretized. Image features are developed for each sub-ROI and subsequently compiled into the final image feature vector. Although this is the first
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Table 4.6: Classification results using image features with augmented states. Comparison is made between baseline ROI and optimal found ROI. Training and testing
set nomenclature refers to the simulated BPM of the set.
Baseline Classifier (ROI)
Augmented with Full State
ID
6.1
6.2
6.3
6.4
6.5
6.6
6.7
6.8
6.9
6.10
6.11
6.12
6.13

Training
Set
47
57
67
78
57 67
78
47 67
78
47 57
78
47 57
67

Kfold
Testing
Error
Set
[%]
47
57
2.38
67
78
Variable
47
2.50
Variable
57
1.50
Variable
67
2.67
Variable
78
2.67
Variable

Score PPV
[%]
[%]
93.3
91.7
75.0
93.3
90.0
75.0
86.7
70.0
88.3
43.3
70.0
88.3
86.7

86.7
86.7
100.0
96.7
86.7
100.0
80.0
93.3
93.3
36.7
50.0
93.3
90.0

NPV
[%]
100.0
96.7
50.0
90.0
93.3
50.0
93.3
46.7
83.3
50.0
90.0
83.3
83.3

Sound Augmented Classifier
(n = 2 Discretization) Augmented
with Full State
Kfold
Testing Score PPV NPV
Error
Set
[%]
[%]
[%]
[%]
47
100.0 100.0 100.0
57
98.3
96.7 100.0
2.75
67
83.3
100.0 66.7
78
91.7
100.0 83.3
Variable 91.7
93.3
90.0
47
61.7
43.3
80.0
2.83
Variable 98.3
96.7 100.0
57
73.3
96.7
50.0
1.67
Variable 83.3
90.0
76.7
67
91.7
100.0 83.3
2.67
Variable 96.7
96.7
96.7
78
88.3
100.0 76.7
2.17
Variable 88.3
100.0 76.7

mention of ROI discretization, the phase augmented ROI is a n = 2 discretization of
the baseline ROI. Although that discretization did not result in improved performance
additional discretization may. A discretization of n = 2 of the augmented classifiers
yield the results provided in Table 4.1. The discretization results in significantly better scores, and lower score deviations which imply less bias towards specific metrics,
a good indication.
In discussing the discretization of the classifiers, the degree of discretization will
be denoted by a subscore. For example phase augmented2 denotes a classifier derived
from the phase augmented ROI which has been discretized into two nodes, or since
the phase augmented ROI was already discretized, is equivalent to baseline4 .
The phase augmented2 classifiers outperform the sound augmented2 classifiers
in every metric, including metric deviation. Even at this discretization level the
classifier does not perform as well on average as compared to the baseline. The one
improvement that the phase augmented2 classifiers offer is an improvement in FPV,
arguably the most significant parameter as it is the worst case metric. This is an
interesting finding as one would expect that CPV and VPV would roughly scale
with improving FPV, however they appear to do so at an decreased rate, perhaps
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Table 4.7: Summary of classifier score results.
Classifier
Baseline
Systole
Diastole
S1
Occurrence
S2
Occurrence
Phase
Augmented
Sound
Augmented
Phase
Augmented
(n = 2)
Sound
Augmented
(n = 2)
Phase
Augmented
(n = 4)
Phase
Augmented
(n = 8)
Phase
Augmented
(n = 16)
Phase
Augmented
(n = 32)

BPMA- BPMA- BPMD- BPMD- BPMCCPV
FPV
CPV
VPV
FPV
[%]
[%]
[%]
[%]
[%]

BPMCVPV
[%]

Average Average
Metric
Metric
Score
Deviation
[%]
[%]
72.34
14.15
57.80
15.24
60.81
11.87

78.75
76.25
68.33

49.03
43.47
42.78

80.42
77.92
68.75

85.00
48.33
70.00

60.84
52.92
48.75

80.00
47.92
66.25

79.99

43.75

80.83

46.77

50.00

47.50

58.13

17.38

70.42

44.03

68.75

60.00

41.67

58.33

57.20

12.10

73.75

43.05

83.75

65.00

49.58

62.09

62.87

15.05

79.58

44.17

80.84

58.33

56.67

57.50

62.85

14.42

74.58

53.89

80.42

76.67

65.42

71.25

70.37

9.54

73.32

50.41

76.25

76.67

57.25

70.83

67.46

10.98

77.50

45.27

78.75

90.00

48.33

84.59

70.74

19.10

72.08

47.78

75.83

88.30

49.58

85.83

69.90

17.52

72.08

51.66

75.83

90.00

48.33

83.34

70.21

16.86

72.50

55.56

73.75

83.33

51.25

80.83

69.54

13.22
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due to the relatively higher initial magnitudes. An additional level of discretization
improved both augmented classifiers performances by a considerable amount, and
so additional discretization levels are applied. Discretization of the only the phase
augmented region was trialed due to the phase augmented classifiers outperforming
the related sound augmented models. The levels are dyadically implemented, up to
32 nodes.
Additional discretization of the ROI does not yield improved results. FPV improves while the other metrics either decrease or remain constant. FPV is theorized
to improve due to the appended images deconstraining the training space. When
developing the ROI image it was previously shown that the image is normalized by
the maximum matrix element of the region. In higher discretizations, several different
normalizations are applied to the image sets resulting in increased region to region
image variation which is believed to deconstain the training space. Decreasing CPV
metrics support this theory as deconstraining would reduce classification potential of
common states.
The baseline metric is not exceeded by any ROI selection/discretization, leaving
few options. The disparity between classifiers is projected to be the result of the
variation seen between unique states in combination with the natural variation of
the in vitro system acoustics. Given the timing nonlinearity of the system it is
believed that similar images from different states and conditions overlap with each
other making identification of each impossible. In order to elicit the potential to
discern similar images apart from each other, the signal state is appended to the
feature vector.
Throughout this work, the state is defined by MAP and heart rate, however the full
state of the signal includes ventricular pressure as well, being that it is a boundary
condition of the LVAD. The full state of the signal is then defined by the following parameters: systolic aortic pressure, diastolic aortic pressure, systolic ventricular
pressure, diastolic ventricular pressure, and heart rate. The SVM feature vectors are
modified by the full state, resulting in the new classifier inputs. Augmentation of the
feature vector is not affected by discretization nor ROI selection.
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Table 4.8: Summary of state augmented classifiers trialed.
Classifier
Baseline
Phase
Augmented
(n = 2)
Phase
Augmented
(n = 32)

BPMA- BPMA- BPMD- BPMD- BPMCCPV
FPV
CPV
VPV
FPV
[%]
[%]
[%]
[%]
[%]

BPMCVPV
[%]

Average Average
Metric
Metric
Score
Deviation
[%]
[%]
78.06
14.35

87.92

50.00

88.33

90.00

69.17

82.92

76.67

50.00

93.33

91.67

78.75

91.67

80.35

15.07

74.59

50.14

75.42

81.67

52.08

79.59

68.91

12.82

To analyze the effects of state augmentation the baseline, phase augmented2 , and
phase augmented32 classifier metrics are requantified. State augmentation results
in significant score improvements for both the the baseline and phase augmented2
models, while the phase augmented32 performs roughly the same. Underperformance
of the phase augmented32 classifier is projected to be the result of the discretization
level. The high level of discretization over-dimensionalizes the feature space (n =
1984) thus augmenting by the n = 5 state vector results in little to no improvement.
Augmentation of the feature vector results in the first instance of a classifier outperforming the baseline classifier (augmented with the state). The phase augmented2
classifier outperforms the baseline in every metric other than BPMA-CPV, with the
most significant improvement being the ability to correctly identify the 67 BPM
states - the most closely timed states (Table 3.3). The most significant improvement
attributed to state augmentation is in the ability to identify foreign and variable
sets (FPV and VPV) - the most desired ability however there is now a dependence
on training state variation. State augmentation constrains the space such that it
requires at minimum two unique BPM training states (Referencing BPMA-FPV).
When trained on a singular BPM state the classifier is completely unable to discern
foreign BPM states. The BPMA-FPV metrics are the result of the models attempting to classify all points as either healthy or unhealthy (flooring/ceiling), an obvious
deficiency.
To determine the scaling of the deficiency the BPMB models are examined. Once
a second BPM state is introduced into the training space the FPV score increases
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for both classifiers (Table 4.1). BPMA is the assumed worst training space while
BPMC would be an assumed improvement over BPMB being that the BPM state
range is increased. As such it would be expected that the FPV for the BPMB models
would fall in-between the FPV range of BPMA and BPMC, which was found to be
true for all augmented state permutations trialed. As the image feature is augmented
with more state information the classifier’s predictive ability increases. Weighting
wise, ventricular pressure appears to carry more significance however it is the least
feasible of the states to practically acquire. The state combination with the highest
practicality and most benefit is the combination of BPM and aortic pressure, however
with a caveat. It makes logical sense to augment the image vector with at minimum
the BPM state however both FPV and VPV suggest otherwise. When the BPM
state is augmented, baseline classifier performance either decreases or stays roughly
the same. No similar consistent trend exists for the phase augmented2 classifier
however there are instances when it does occur. Given this trend inconsistency no
definitive statement can be made regarding how BPM state augmentation affects
model predictive ability.
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Table 4.9: Summary of optimal model foreign and variable predictive score based on
various augmented state combinations.
BPMB
BPMC
FPV VPV FPV VPV
Classifier
Augmented States
[%]
[%]
[%]
[%]
None
60.42 68.61 60.84 80.00
BPM
53.19 58.33 52.49 70.41
Aortic Pressure
58.75 63.89 60.84 73.75
Baseline
BPM
53.75 58.06 53.33 69.50
Aortic Pressure
Aortic Pressure
70.97 74.17 71.67 82.92
Ventricular Pressure
BPM
Aortic Pressure
65.97 72.50 69.17 82.92
Ventricular Pressure
None
56.25 75.56 65.42 71.42
BPM
57.36 72.22 69.58 72.49
Phase Augmented
Aortic Pressure
59.86 72.22 66.67 71.67
BPM
(n = 2)
58.06 72.50 65.42 70.42
Aortic Pressure
Aortic Pressure
67.86 81.95 80.41 87.50
Ventricular Pressure
BPM
Aortic Pressure
65.42 81.94 78.75 91.67
Ventricular Pressure
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Chapter 5
Conclusion
The phase augmented2 classifiers are the most practical identifiers of conditions derived from this work. On average they perform the best without state augmentation
(neglecting the baseline) and with augmentation they consistently outperform the
baseline. Unfortunately the most significant states appear to be ventricular pressures
which are the least practical to acquire. With that being the case, the selection of
the optimal ROI is even more important in developing the most robust classifier.
Due to the nonlinear timing of the S1 and S2 finding a specific frame of the spectra
image that manifests condition is difficult. Due to this the most logical choice of
ROI may be one which spans the maximum time range, accounting for the COI,
however all ROIs parsed in this work are derived from physiological parameters or
empirical observations, and thus are justified. The alternative option is to preprocess
the acquired acoustics such that the space that the states span is reduced. Doing so
would reduce the variation in sound occurrences, possibly allowing for a more specific
ROI to be discerned, and ultimately a more accurate classifier can be developed.
Given this approach the entirety of the HMAPR can be parsed into subsections, each
with a unique ROI and derived classifier model. Discretization of the HMAPR would
theoretically result in greater classification potential however is less practical as it
would require unique preprocessing for each patient, speaking in terms of human
trials. However given this theory, in a proof of concept baseline ROI classifiers were
developed for different levels of HMAPR discretization and tested against the variable
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Figure 5-1: Classification scores of a discretized HMAPR using baseline ROI with
and without full state augmentation.
BPM set. All four BPM states are used in developing the classifier, and the SVM
parameters were optimized in the same manner as was discussed in Chapter 4.
The results are promising (Figure 5-1) in that state augmentation continues to
improve score. It should be noted that the training spaces and testing spaces are not
constrained to have a consistent number of states which manifests in the scores of
the n = 8 subregion spanning a systolic pressure of [90,100] and diastolic pressure of
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[70,80]. Due to the difficulty in tuning the simulator to the desired pressure states,
fine, consistent, and uniform state resolution over the HMAPR is not possible - thus
the approach that was taken. The next iterations of testing should further parse
down the HMAPR, while still examining discretization, and more data should be
collected at more BPM states. Additionally, training a classifier on variable BPM
state data should be trialed, however practically doing so would require a new trigger
function generation procedure. Related to hardware/physical parameters, additional
stethoscope locations (Increased attention to at the VAD surface) should be examined
along with more occlusion conditions and possibly extending identification to inlet
blockage as well.
This work fails to quantify how training space density and state proximity affect
classification results, which is a serious issue. It was shown when iterating classifiers
from BPMA to BPMD that the density and spacing of the training space has a direct
correlation to predictive potential. Discretizing the HMAPR produced insufficient
training points in the [90,100][70,80] partition, which would assumedly skew nondiscretized ROI classifiers when attempting to classify within this region. Subsequent
work should study this metric intensively. Projected metrics can be score within a
chosen training state radii, score vs. closest proximity, and ROI proximity score.
The spectras generated are of fairly high quality, however due to the COI, there is a
loss of feasible ROI space. To account for this one of two options should be examined:
1) Use a wavelet transform variant that is less shift variant so that extraneous data
can be appended to the signal such that the original signal is not affected by edge
effects. 2) Append the minimum amount of data to adjust for the COI. Option 2 is
the easier of the options however requires that information about the original signal
(sampling rate, trigger/EKG, and BPM) are used to parse the ROI.
The classifier family, SVM, was chosen out of practicality not so much functionality. Other classifiers (deep learning algorithms) such as convolutional neural networks
have been proven to perform image recognition/classification to very high degrees of
accuracy however are more difficult to develop and implement. The next step in progressing the classification potential of the acoustic signal would be to develop a deep
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learning classifier.
This work shows that outlet occlusion classification is feasible using only the sound
produced from an LVAD along with the related EKG signal. The degree to which
this is feasible scales with the states augmented to the derived image feature vectors,
however information such as aortic pressure can be noninvasively acquired making
it a feasible application. At minimum, the heart simulator resulting from this work
appears to be a fair mimic for developing a diagnostic method. Even though control of
the system is heuristic and manual, the signals derived from it share similar spectral
properties with the in vivo data acquired, and are characterized by nonlinearities/nonstationarities like the physiological organ system.
The results presented herein support the feasibility of further developing the image
recognition algorithm for practical use. The HMAPR space is induced with significant
variation, however fair classifier performance is still feasible. This work suggests that
there does exist a spatial boundary in which device condition can be evaluated against.
In a more practical scenario a patient is baselined at implantation, generating the
boundary (1 class classifier model). In subsequent tests, new data is acquired and
tested against the boundary to determine if any of the newly acquired data is classified
as an outlier, ultimately indicating a health concern.
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